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ABSTRACT 
 
Cancer is driven by numerous cellular dysregulations such as increased 
proliferation, decreased apoptosis, increased vascularization, and evasion of immune 
surveillance. As such, it is unlikely that inhibiting only one of these disease hallmarks 
will cause a lasting clinical response. The objective of this work is to modulate 
intracellular signaling, endothelial expansion, and immune cell activation in human and 
mouse models of cancer to better inform the development of new antibody therapeutics.  
The contribution of fourteen growth factors to receptor tyrosine kinase (RTK) 
driven chemotherapy resistance in nine pancreatic ductal adenocarcinoma and fifteen 
ovarian cancer cell lines was assessed using phosphorylation of Protein Kinase B (AKT) 
as a readout for pro-survival signaling via western blot and ELISA. Results revealed 
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redundancy between Insulin-Like Growth Factor Receptor (IGF-1R) and Epidermal 
Growth Factor Receptor 3 (ErbB3) signaling. In pancreatic cancer cell lines, a tetravalent, 
bispecific antibody co-targeting IGF-1R and ErbB3 (istiratumab/MM-141) blocked 
growth factor induced pro-survival signaling and enhanced chemotherapy-induced 
apoptosis. Istiratumab also improved the in vivo efficacy of gemcitabine and nab-
paclitaxel in two cell line-derived xenograft (CDX) models and one patient-derived 
xenograft (PDX) model of pancreatic cancer. In ovarian cancer cell lines, cell-surface 
IGF-1R expression correlated significantly with in vitro cisplatin and paclitaxel 
sensitivity, and istiratumab prevented chemotherapy induced AKT phosphorylation. 
Furthermore, istiratumab enhanced the in vivo efficacy of paclitaxel, pegylated-liposomal 
doxorubicin, and cisplatin in an ovarian cancer CDX model.  
The role of the cytokine Tumor Necrosis Factor (TNF) has been studied within 
the tumor microenvironment. Firstly, the in vitro human umbilical vein endothelial cell 
(HUVEC) model of angiogenesis revealed TNF-mediated TNF receptor 1 (TNFR1) 
activation to be a driver of endothelial tube maintenance. Secondly, an investigation into 
the driving mechanism of action for a TNFR2-targeting mouse IgG2a (Y9/MM-401) in 
eight in vivo mouse syngeneic models of cancer showed that cancer cell TNFR2 
expression does not drive in vivo efficacy, rather it promotes Fc receptor mediated 
agonism of tumor infiltrating CD8 positive effector T cells. These data support TNFR2 as 
a possible therapeutic target for the treatment of cancer.  
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CHAPTER 1: INTRODUCTION 
1.1 Background and Significance 
 A cancer diagnosis can be life altering both for a patient and for their loved ones, 
frequently causing a threat to one’s self-identity and feelings of stigmatization (Knapp, 
Marziliano, and Moyer 2014). With the advent of novel anti-cancer therapeutics, 
however, oncologists are now capable of occasionally inducing lasting clinical responses 
in patient populations with previously thought incurable disease (Jun Tang et al. 2018). 
Moreover, there was a remarkable decline of 27% in newly diagnosed cancer patients 
between 1991 and 2016 (R. L. Siegel, Miller, and Jemal 2019), attributed to factors 
including decreased exposure to carcinogens (such as cigarette smoke and nitrates in 
preserved meats) and the arrival of novel cancer detection methods. Despite these 
improvements, this disease remains a leading cause of death in the United States of 
America accounting for almost 22% of the total deaths (Center for Health Statistics 
2017). Although a cancer diagnosis is no longer necessarily terminal and the cancer 
incident rate has had a favorable downward trend, much research remains to be done with 
regards to better understanding the intricacies of this disease to develop strong new 
therapeutic options.   
In 2011, Robert Weinberg published a review entitled “Hallmarks of cancer: the 
next generation” which provides a broad perceptive into the diverse drivers of cancer and 
describes what treatment approaches are under investigation to target each of these 
drivers (Hanahan and Weinberg 2011). Weinberg outlined the ten primary drivers or 
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“hallmarks” of cancer as including sustained proliferative signaling, evasion of growth 
suppression, evasion of immune destruction, enabling replicative immortality, high 
tumor-promoting inflammation, activated invasion and metastasis, induction of 
angiogenesis, genomic instability, resistance to cell death, and dysregulation of cellular 
energetics. Although novel treatments targeting each of these hallmarks in one shape or 
form are currently undergoing investigation, the reality of this disease is that pronounced 
genomic instability commonly leads to several of these hallmarks simultaneously being 
activated (Yhap et al. 1999)(Petty et al. 1998)(Dokic et al. 2015). Drugging only one of 
these disease liabilities will not likely lead to a durable response in the clinic (Renouf and 
Moore 2010). An understanding of the interplay between these hallmarks is vital to the 
improving the likelihood of a cancer patient being cured. This work seeks to develop a 
mechanistic understanding of how simultaneously targeting multiple cancer hallmarks 
with therapeutic antibodies within the tumor microenvironment (TME) can improve anti-
cancer efficacy.  
1.2 Cell surface receptors and cancer 
 During the oncogenic process, cancer cells are able to grow and sustain 
themselves in part by coopting the body’s natural regenerative processes. For example, 
wound healing involves tissue growth driven through intercellular signaling processes 
(Barrientos et al. 2008).  Likewise, within the tumor microenvironment the presence of 
numerous diverse growth factors and cytokines can induce cell proliferation and cell 
survival, activating several of Weinberg’s hallmarks (Foster et al. 2018). These factors 
can be found as either soluble forms in solution, or membrane bound on a neighboring 
3 
 
cell. They can originate from the blood in an endocrine manner, from a neighboring cell 
in a paracrine manner, or from the same cell on which it will act in an autocrine manner. 
These proteins will typically serve as a ligand for a cell surface receptor, which upon 
binding can induce conformational changes in the receptor leading to activation of 
intracellular signaling cascades.  
Many growth factors such as insulin (Ins), insulin-like growth factor (IGF), 
epidermal growth factor (EGF), betacellulin (BTC), heregulin (HRG), fibroblast growth 
factors (FGFs), platelet derived growth factor (PDGF), and others bind to a class of cell 
surface receptors called receptor tyrosine kinases (RTK). These receptors have numerous 
tyrosine residues in their cytoplasmic domain which upon phosphorylation become 
capable of recruiting adaptor proteins to aid in the propagation of downstream signaling, 
and have been shown to increase cell survival and proliferation within the TME (Sepp-
Lorenzino et al. 1996). An additional family of factors such as lymphotoxin (LT), tumor 
necrosis factor (TNF), OX40 ligand (OX40L), FAS ligand (FASL), B-cell activating 
factor (BAFF), and others fall into the tumor necrosis factor superfamily (TNFSF) and 
bind their respective trimeric TNFSF receptors, cell surface proteins which can alter the 
activation of tumor infiltrating immune cells thereby leading to either cancer progression 
or regression (Ham et al. 2016).  
1.3 Receptor tyrosine kinases 
Although over thirty RTK targeting drugs are approved for the treatment of 
cancer (Fauvel and Yasri 2014), there remain further therapeutic opportunities to explore 
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within this class of receptors. For example, when the HRG growth factor is produced in 
either an autocrine or paracrine manner within the tumor microenvironment, it can bind 
to its receptor ErbB3. ErbB3, despite belonging to the RTK family, lacks an intracellular 
kinase domain, and when inactive exists as a monomer (Steinkamp et al. 2014). Its 
phosphorylation is dependent on its dimerization with a neighboring ErbB family 
member (ErbB1, 2 or 4) following ligand binding. This binding event induces receptor 
transphosphorylation, and activates downstream pro-survival PI3K signaling or 
proliferative MAP kinase signaling (Muthuswamy, Gilman, and Brugge 1999). The 
specific binding partner for ErbB3 impacts the downstream signaling output, with ErbB3 
dimerizing with ErbB2 (HER2) preferentially leading to PI3K activation or ErbB3 
dimerizing with ErbB1 (EGFR) preferentially leading to MAPK activation (Kirouac et al. 
2016).  
On the other hand, the insulin family of cell surface RTKs are activated via a 
different paradigm. The receptors for insulin and insulin-like growth factors 1 and 2 
(IGF-1 and IGF-2), the insulin receptor (IR) and IGF1 receptor (IGF1R), exist as 
preformed dimers on the cell surface, and each partner transphosphorylates the other 
following ligand engagement (Simpson et al. 2017). These preformed dimers can be 
either two insulin receptors, two IGF1Rs, or one IR and one IGF1R. Insulin binds to only 
IR containing receptors, IGF1 binds to only IGF1R containing receptors, whereas IGF2 
binds to all forms of this receptor complex (Simpson et al. 2017). Unlike HRG, the 
insulin family of growth factors can act in an endocrine manner (Pollak, Schernhammer, 
and Hankinson 2004). Like HRG, IGF-1 may also active PI3K or MAPK signaling 
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(Menu et al. 2004). The IGF receptor 2 (IGF2R) lacks tyrosine phosphorylation sites of it 
“kinase dead”, and acts as a sink for IGF-2 the tumor microenvironment to decrease 
growth factor induced proliferative or pro-survival signaling, and its expression is 
positively associated with response to chemotherapy and patient survival in non-small 
cell lung cancer patients (Z. Tian et al. 2014). Despite having been the subject of 
significant clinical investigation, no drugs are approved for inhibiting either ErbB3 
(Mishra et al. 2018) or IGF1R (Basu, Olmos, and de Bono 2011).  
In addition to being able to activate proliferative and pro-survival signaling within 
the tumor microenvironment, growth factors have been shown to be capable of inducing 
chemotherapy resistance (Niepel et al. 2013). The cytotoxic chemotherapies have been 
shown to be highly efficacious at treating cancer patients, despite numerous toxicities. 
Elucidating which growth factors drive chemotherapy resistance enables the development 
of novel therapeutic agents.  
Furthermore, it has been shown that several of IGF-1 and HRG expression can be 
regulated by the same FOXO transcription factors (Chandarlapaty et al. 2011). FOXO 
transcription factors are themselves inhibited by PI3K activation (Chandarlapaty et al. 
2011), meaning that when PI3K signaling is decreased by inhibiting one RTK, the 
expression of other RTKs will be increased on the cell surface to compensate 
(Chandarlapaty et al. 2011). Given this compensatory upregulation in RTKs, elucidating 
how the expression of RTKs covaries will help inform the novel design of anti-cancer 
combinations. 
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1.4 Tumor necrosis factor receptor super family  
Outside of the RTK family of cell surface receptors, the tumor necrosis factor 
receptor superfamily (TNFRSF) of proteins is also capable of activating cell signaling 
cascades characterized numerous of Weinberg’s hallmarks. Similarly to RTKs, TNFSFRs 
are activated upon ligand binding by cytokines such as tumor necrosis factor alpha 
(TNF). It has been reported that upon stimulation of cells with this cytokine within the 
tumor microenvironment it is possible to induce cancer cell death (Sugarman et al. 1985), 
cancer cell proliferation (Sugarman et al. 1985), immune system activation (Y. L. Wang 
et al. 1989), immune system inhibition (Chen et al. 2007), inflammation (Pikarsky et al. 
2004), differentiation (B. Zhou et al. 2015), and endothelial expansion and angiogenesis 
(B. Zhou et al. 2015). This paradoxical, pleiotropic phenotypic output from a single 
biological input is in large part due to the heterogenous and mixed cell population found 
in the tumor microenvironment. This cytokine has different effects on different cell types 
infiltrating into the tumor microenvironment such as lymphocytes and endothelial cells, 
and therefore the biological outcome within a patient’s tumor following expression of 
TNF is likely determined by the specific balance of each of these infiltrating populations 
and their inter-regulation. Significant clinical examination of systemic TNF 
administration for the treatment of a variety of cancer types was performed over the 
course of 46 clinical trials with limited success (Roberts et al. 2011), indicating that either 
further research is needed to understand how to therapeutically modulate this factor and 
its pathway for an anti-tumor effect or there is no anti-cancer therapeutic potential in 
modulating TNF. Given that the details of the balance between these phenotypic outputs 
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remain poorly elucidated, a better understanding could lead to the development of the 
next generation of TNF modulating therapies for the treatment of cancer in the clinic.  
As a member of the tumor necrosis factor superfamily of cytokines, TNF is first 
presented as a membrane bound ligand which can either directly bind its target receptor 
on a neighboring cell or be cleaved from the membrane into a soluble form prior to 
binding its receptor. TNF’s two target receptors, tumor necrosis factor receptors 1 and 2 
(TNFR1 and TNFR2), can also be cleaved from the membrane into a soluble form. These 
shed receptors can act as a sink for TNF within a microenvironment and thereby decrease 
localized inflammation (X. D. Zhang et al. 2000). Using soluble TNF receptor to 
decrease inflammation has been clinically validated for the treatment of rheumatoid 
arthritis with the widely used drug ENBREL (Etanercept) which is a soluble TNFR2 and 
Fc fusion protein (Peppel, Crawford, and Beutler 1991). Despite both binding to TNF, 
TNFR1 and TNFR2 have been shown to have non-redundant functions (Tartaglia et al. 
1991), and different downstream signaling networks have been proposed for each 
receptor. Interestingly, it has been shown that membrane bound TNF preferentially 
activates TNFR2 over TNFR1 and induced immune cell expansion (Grell et al. 1995), 
whereas soluble TNF can induce cytotoxicity in cancer cell lines through TNFR1 
activation (Tartaglia et al. 1991).  This phenomenon may be due to differences in affinity 
for the membrane bound TNF between these two receptors (Yoshida et al. 2006). Despite 
these proposed different roles of TNFR1 and TNFR2, expression of TNFR2 is not 
restricted to immune cell subpopulations (Tartaglia et al. 1991)(Tam et al. 2019), leading 
us to question what role TNFR2 may be playing on the cancer cells themselves. It was 
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first proposed in 1998 that TNFR1 and TNFR2 can cooperatively bind TNF to induce 
nitric oxide synthesis in mouse macrophage cells (Riches et al. 1998), then shown in 
2001 that TNFR2 can enhance TNF cytotoxicity in human cancer cell lines (Lu, Fang, 
and Chen 2001). The proposed molecular mechanism for this cooperative signaling was 
termed “ligand passing,” where TNFR1 and TNFR2 form heterocomplexes bound 
through a TNF intermediate to enhance TNF binding to TNFR1 (Pinckard, Sheehan, and 
Schreiber 1997).  It has recently been shown that therapeutically targeting TNFR2 with 
anti-TNFR2 monoclonal antibodies in preclinical models of mouse immunocompetent 
syngeneic cancer is very efficacious at inhibiting tumor growth (Tam et al. 2019). 
Understanding the role of TNFR2 on the endothelial cells, cancer cells, and immune cells 
is vital in the development of a new drug targeting this receptor when considering patient 
safety. Determining how the interplay between TNFR1 and TNFR2 alters response in 
each of these cell populations will potentially find a mechanism through which to induce 
a stronger anti-cancer response with anti-TNFR2 therapeutics. 
1.5 Thesis rationale and outline 
The objective of this work is to elucidate potential biological susceptibilities of 
cancer to better inform the development of novel therapeutics. In chapters 2 and 3 an 
investigation into the contribution of growth factor induced receptor tyrosine kinase 
(RTK) signaling to chemotherapy resistance in pancreatic ductal adenocarcinoma and 
ovarian cancers was performed, revealing redundancy between Insulin-Like Growth 
Factor Receptor (IGF-1R) and Epidermal Growth Factor Receptor 3 (ErbB3) induced 
pro-survival signaling. A tetravalent, bispecific antibody co-targeting these RTKs 
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(istiratumab) was shown to improve the efficacy of standard of care chemotherapy 
treatment in vivo in both of these cancer indications. Additionally in chapters 4 and 5, the 
pleiotropic Tumor Necrosis Factor (TNF) has been studied within the tumor 
microenvironment with a focus on elucidating which phenotypic outcomes are driven 
through either TNF receptor 1 or 2 (TNFR1 and TNFR2 respectively). A study of TNF’s 
effects on tumor cells, endothelial cells, and immune cells revealed TNFR2 as a 
therapeutic target for the treatment of cancer.  
1.5.1 Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) kills over 213,000 people worldwide 
each year and has the least favorable one- and five-year survival rates of all cancer 
subtypes (Han and Von Hoff 2013). After diagnosis with advanced metastatic disease, a 
patient treated with the standard of care gemcitabine chemotherapy regimen may only 
have a median survival likelihood of 5.7 months (Burris et al. 1997). In 2007 the addition 
of erlotinib (an ErbB1/EGFR targeting small molecule) to gemcitabine was approved by 
the Federal Drug Administration after improving median overall survival by only about 
two weeks despite significantly increased toxicity (Moore et al. 2007). More recently in 
2013, the combination of nanoparticle albumin bound (nab-) paclitaxel to gemcitabine 
significantly improved median patient overall survival to 8.5 months (Von Hoff et al. 
2013). Even with this improvement, a cure for pancreatic cancer remains elusive.  
In part, the normal physiological function of the pancreas is to produce insulin for 
glycemic control. Pancreatic tumors can coopt the localized high levels of insulin to 
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induce cancer cell survival and proliferation (M. T. Chan et al. 2014). Given this feature 
and the known efficacy of erlotinib at treatment pancreatic cancer, we hypothesize that 
therapeutically inhibiting growth factor receptors may be efficacious for the treatment of 
pancreatic cancer. To assess which growth factors pancreatic cancer is most dependent 
upon we screened a panel of nine pancreatic cancer cell lines in vitro, revealing IGF-1 
and HRG as the most potent growth factors with regards to PI3K pro-survival activation. 
Profiling of pancreatic cancer patient samples revealed IGF1, HRG, and their respective 
receptors to be highly expressed in the metastatic pancreatic cancer patient population. 
Using the tetravalent, bispecific antibody targeting IGF-1R and ErbB3, istiratumab, we 
showed this inhibition combination was able to restore sensitivity to chemotherapy in 
vitro in these cell line models lost due to growth factor stimulation and enhanced the 
degree of cell death induced by chemotherapy alone. This antibody was also able to 
enhance the in vivo efficacy of the gemcitabine + nab-paclitaxel in three models of 
pancreatic cancer.  
1.5.2 Ovarian cancer 
 Affecting over 238,000 women a year across the globe (Torre et al. 2015), ovarian 
cancer has just over a 50% 5-year survival rate (Helm and States 2009). While cisplatin 
chemotherapy is currently considered an efficacious front-line treatment for this disease 
(Helm and States 2009), the low 5-year survival rate reveals a need for novel agents to 
treat this disease in second line. Recently the advent of poly(adenosine diphosphate–
ribose) polymerase (PARP) inhibitors has considerably improved ovarian cancer patient 
survival, however this regimen is only efficacious in patients harboring BRCA mutations 
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(Cortesi, Toss, and Cucinotto 2018). Further research is needed to help patients who fall 
outside of this category.  
It has been reported that high IGF-1 levels can increase a patient’s risk for 
developing ovarian cancer (Cortesi, Toss, and Cucinotto 2018), and that HRG can sustain 
ovarian cancer cell proliferation (Sheng et al. 2010). As such, we hypothesized that the 
anti-IGF1R anti-ErbB3 bispecific antibody used in the pancreatic cancer study, 
istiratumab, will also enhance chemotherapy efficacy in ovarian cancer. We first profiled 
15 ovarian cancer cell lines for sensitivity to cisplatin and paclitaxel (two chemotherapies 
used for the treatment of ovarian cancer). We determined that cell surface IGF1R levels 
predict basal chemotherapy sensitivity and went on to reveal that IGF-1 and IGF-1R are 
expressed in tissue taken from ovarian cancer patient biopsies. A signaling screen 
revealed that dual blockade of IGF-1R and ErbB3 in ovarian cancer cell lines was able to 
block both PI3K pro-survival and MAP kinase proliferative signaling cascades induced 
by IGF-1 and HRG stimulation. Treatment with cisplatin, paclitaxel, or doxorubicin was 
shown to increase responsiveness to IGF-1 or HRG induced PI3K signaling in vitro, and 
in vivo treatment of mice with the bispecific antibody istiratumab was able to enhance 
response to these three chemotherapies.  
1.5.3 TNF, TNFR2, and angiogenesis 
 It has been reported that TNF can either induce or inhibit angiogenesis under 
different circumstances (Fajardo et al. 1992)(Frater-Schroder et al. 1987). Given that 
TNFR1 and TNFR2 have been reported to be expressed on endothelial cells 
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(Leeuwenberg et al. 1995) we sought to elucidate how specifically inhibiting TNFR1 or 
TNFR2 will alter angiogenic response. Having first optimized an in vitro assay for 
interrogating angiogenesis on primary human cells using primary human umbilical vein 
endothelial cells (HUVEC), we then use open-source software to computationally 
quantify degree of angiogenesis under different treatment conditions. We demonstrate 
that TNF is able to enhance endothelial tube maintenance. TNF induced endothelial tube 
maintenance revealed itself to be driven by TNF binding to TNFR1, and inhibition of 
TNFR2 had no effect.  
1.5.4 Elucidating driving cell populations of anti-TNFR2 in vivo efficacy 
TNFR2 has been reported to be expressed both on cancer cells (Y. W. Zhang et al. 
2019) and immune cells (Chen et al. 2007) within the TME. We hypothesize that TNFR2 
expression on each of these cell populations is contributing to in vivo efficacy of an anti-
TNFR2 therapeutic. We began by showing that an anti-TNFR2 antibody has therapeutic 
activity across a diverse panel of eight syngeneic cancer models in vivo. No relationship 
was observed between TNFR1 and TNFR2 expression on the cancer cell lines and anti-
TNFR2 in vivo efficacy. Additionally, neither cell surface TNFR1 nor TNFR2 expression 
levels altered in vitro signaling response to TNF stimulation with regards to degree of 
activation or which signaling nodes become activated. Interestingly, knock out of TNFR2 
from cancer cell lines did decrease in vitro responsiveness to TNF, suggesting that the 
receptor is playing a role in in vitro cancer cell line response to TNF. Remarkably, in vivo 
efficacy was maintained when tumor TNFR2 was knocked out from in vivo models. 
Furthermore, anti-TNFR2 in vivo activity was lost when tested in nude mice lacking a 
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mature T cell population and when tested in mice depleted of CD8 effector T cells. Taken 
together, these data suggest that TNFR2 on cancer cell lines does not contribute to anti-
TNFR2 in vivo efficacy. Ex vivo culture of CD8 T cells revealed the anti-TNFR2 
antibodies are capable of directly agonizing both proliferation and activation of this cell 
population. This activation revealed itself to be dependent on Fc receptor engagement, 
which is the likely mediator of receptor clustering to induce CD8 T cell agonism.  
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CHAPTER 2: DUAL INHIBITON OF IGF-1R AND ERBB3 ENHANCES THE 
ACTIVITY OF GEMCITABINE AND NAB-PACLITAXEL IN PRECLINICAL 
MODELS OF PANCREATIC CANCER 
2.1 Abstract 
Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in 
pancreatic cancer pathophysiology, promoting cancer cell survival and therapeutic 
resistance. Assessment of IGF-1R inhibitors in combination with standard-of-care 
chemotherapy, however, failed to demonstrate significant clinical benefit. The aim of this 
work is to unravel mechanisms of resistance to IGF-1R inhibition in pancreatic cancer 
and develop novel strategies to improve the activity of standard-of-care therapies. 
Experimental Design: Growth factor screening in pancreatic cancer cell lines was 
performed to identify activators of prosurvival PI3K/AKT signaling. The prevalence of 
activating growth factors and their receptors was assessed in pancreatic cancer patient 
samples. Effects of a bispecific IGF-1R and ErbB3 targeting antibody on receptor 
expression, signaling, cancer cell viability and apoptosis, spheroid growth, and in vivo 
chemotherapy activity in pancreatic cancer xenograft models were determined. 
Results: Growth factor screening in pancreatic cancer cells revealed insulin-like 
growth factor 1 (IGF-1) and heregulin (HRG) as the most potent AKT activators. Both 
growth factors reduced pancreatic cancer cell sensitivity to gemcitabine or paclitaxel in 
spheroid growth assays. Istiratumab (MM-141), a novel bispecific antibody that blocks 
IGF-1R and ErbB3, restored the activity of paclitaxel and gemcitabine in the presence of 
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IGF-1 and HRG in vitro. Dual IGF-1R/ErbB3 blocking enhanced chemosensitivity 
through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 
degradation. Addition of istiratumab to gemcitabine and nab-paclitaxel improved 
chemotherapy activity in vivo. 
Conclusions: Our findings suggest a critical role for the HRG/ErbB3 axis and 
support the clinical exploration of dual IGF-1R/ErbB3 blocking in pancreatic cancer. 
2.2 Translational Relevance 
Metastatic pancreatic cancer remains a leading cause of cancer mortality. High 
levels of IGF-1R in pancreatic cancer are associated with higher tumor grade and 
decreased survival. However, IGF-1R inhibitors have failed to show significant clinical 
benefit. Our studies show that the HRG/ErbB3 axis is critical to pancreatic cancer 
progression and therapeutic resistance to IGF-1R inhibition. Both IGF-1R and ErbB3 can 
serve as drivers of tumor growth and resistance/tolerance to standard of care 
chemotherapy. Dual targeting of the IGF-1R and ErbB3 pathways with the novel 
bispecific antibody istiratumab increases the activity of standard-of-care chemotherapies. 
These data provide mechanistic insight into pancreatic cancer resistance to IGF-1R 
inhibitors and identify novel translatable treatment strategies for the disease. 
2.3 Introduction 
Pancreatic cancer remains a leading cause of cancer mortality (“Cancer Facts and 
Statistics 2015 | Research | American Cancer Society” n.d.). The 5-year overall survival 
(OS) rate for pancreatic ductal adenocarcinoma (PDAC) is only 5% to 10% (Shin and 
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Canto 2012). The most effective first-line treatments for patients with metastatic disease 
include a combination of gemcitabine with nab-paclitaxel (Von Hoff et al. 2013), and a 
four-drug combination, consisting of leucovorin, fluorouracil, irinotecan, and oxaliplatin 
(FOLFIRINOX)(Conroy et al. 2011). Median overall survival (mOS) with these regimens 
is 8.5 and 11.1 months, respectively (Von Hoff et al. 2013)(Conroy et al. 2011). Despite 
the largest increase in survival for FOLFIRINOX, this regimen is characterized by 
substantial toxicity and is usually restricted to patients with good performance status. 
Recently, nanoliposomal irinotecan (Onivyde), in combination with fluorouracil and 
leucovorin, was approved by the US Food and Drug Administration for the treatment of 
patients with metastatic disease who previously received gemcitabine-based therapy 
(Andrew H Ko 2016)(Wang-Gillam et al. 2016). Although this combination extends 
survival and has a manageable safety profile, mOS is 6.1 months (Wang-Gillam et al. 
2016). Therefore, there remains an urgent need for novel therapies with better efficacy to 
further improve patient outcomes in this deadly neoplasm. 
Insulin-like growth factor receptor 1 (IGF-1R) is a receptor tyrosine kinase (RTK) 
that has a key role in cancer pathophysiology, promoting cancer cell survival and 
proliferation, tumor growth, and therapeutic resistance (Kurmasheva and Houghton 
2006)(Li, Pourpak, and Morris 2009). Ligands of IGF-1R may be delivered through 
endocrine or autocrine/paracrine signaling in aggressive cancers (Pollak, Schernhammer, 
and Hankinson 2004). Increased levels of insulin-like growth factor-1 (IGF-1) are 
associated with enhanced cancer risk and resistance to chemotherapies across multiple 
cancer indications; including esophageal, colon, breast, prostate, and lung cancers (J. M. 
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Chan et al. 1998)(Adachi et al. 2014)(Hankinson et al. 1998)(Y. C. Liu et al. 2002)(Ma et 
al. 1999)(Dziadziuszko, Camidge, and Hirsch 2008). High levels of IGF-1 and IGF 
binding proteins have been detected in the blood of patients with pancreatic cancer, 
correlating with enhanced IGF-1R phosphorylation in tumor tissue (Jiang, Gu, and Chen 
2014). High expression of IGF-1R in pancreatic cancer is associated with higher tumor 
grade and decreased survival (Hirakawa et al. 2013). This provided the rationale for the 
development and clinical testing of IGF-1R inhibitors in pancreatic cancer. However, 
despite evidence that IGF-1R pathway signaling is implicated in tumor progression, as 
well as promising early-phase clinical data with IGF-1R targeting antibodies (Kindler et 
al. 2012)(McCaffery et al. 2013), larger phase III clinical trials failed to show an 
advantage of targeting IGF-1R in pancreatic cancer (Fuchs et al. 2015). 
Resistance to IGF-1R targeted therapies remains a major challenge. Mechanisms 
of resistance include a compensatory re-activation of downstream PI3K/AKT/mTOR 
signaling (J. B. Fitzgerald et al. 2014). This hypothesis is supported by findings in 
various cancer types, which reveal an interplay between IGF-1R and other RTKs (Huang 
et al. 2010)(Knowlden et al. 2011)(Jia et al. 2013)(Z. Zhang et al. 2014). Preclinical 
studies have shown that IGF-1R inhibition upregulates insulin receptor signaling in 
malignancies (McCaffery et al. 2013)(J. B. Fitzgerald et al. 2014)(Eser et al. 2014), 
whereas further studies suggest that ErbB receptor signaling confers resistance to IGF-1R 
inhibition (J. B. Fitzgerald et al. 2014)(Knowlden et al. 2011). 
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Despite the well-characterized implications of IGF-1R signaling in pancreatic 
cancer, knowledge and understanding of resistance to IGF-1R inhibitors in pancreatic 
tumors are limited. This study sought to identify potent activators of pancreatic cancer 
cell survival and growth, determine pathways that promote desensitization to gemcitabine 
and paclitaxel, and reveal strategies to re-sensitize pancreatic cancer cells to standard of 
care treatment. Our data highlight the role of the HRG/ErbB3 axis in pancreatic cancer 
and the therapeutic potential of dual IGF-1R/ErbB3 inhibition in this setting, supporting 
the clinical exploration of a novel bispecific IGF-1R/ErbB3 inhibitor as a therapeutic for 
the treatment of pancreatic cancer. 
2.4 Materials and Methods 
2.4.1 Cell lines and reagents 
 All cell lines in this study were obtained from the ATCC, except KP-4 (RIKEN 
Bioresources Cell Bank). Cell lines were confirmed negative for mycoplasma prior to 
use, maintained according to manufacturer recommendations (Supplementary Table 2.S1) 
and propagated for less than 8 weeks after initial plating. All recombinant human growth 
factors were obtained from PeproTech, except IGF-1 (R&D Systems), HRG (R&D 
Systems), and insulin (Sigma) as described in Supplementary Table 2.S2. 
2.4.2 In vitro signaling experiments 
 Unless otherwise mentioned, cells were seeded into 96-well tissue culture plates 
(Costar) at 20,000 cells/well in complete media supplemented with 10% FBS. The 
following day, cells were synchronized by 24-hour serum starvation in media with 2% 
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FBS. Signaling experiments were stopped with a cold PBS wash, and cell lysates were 
generated with Mammalian Protein Extraction Reagent (Thermo Scientific) 
supplemented with phosphatase and protease inhibitor pellets (Roche) and 150 mmol/L 
sodium chloride (Sigma). For receptor ubiquitination experiments, cells were seeded into 
15 cm dishes, pretreated with the proteasome inhibitor epoxomicin (Sigma) for 2 hours, 
and treated as indicated. Cells were harvested and cell lysates clarified by centrifugation 
at 13,000 rpm at 4C. Receptors were immediately immunoprecipitated using Dynabeads 
(Life Technologies) with IGF-1R (Cell Signaling Technology) or ErbB3 (R&D Systems) 
antibodies. For gemcitabine- and paclitaxel-induced upregulation of IGF-1R and ErbB3 
receptors, cells were seeded into 10-cm dishes and lysates were clarified by 
centrifugation at 13,000 rpm for 10 minutes at 4C. 
2.4.3 Caspase 3/7 cleavage activity experiments 
 Cells were seeded into 96-well tissue culture plates at 5,000 cells per well in 
media containing 2% FBS. The following day, media was replaced with media containing 
2% FBS and the Essen BioSciences IncuCyte Caspase-3/7 Green Apoptosis Assay 
Reagent (catalog no. 4440), then immediately treated in octuplicate as indicated. 
Caspase-3/7 activity was measured 16 hours following start of treatment in the IncuCyte 
imager, and then normalized to cell density within each well. 
2.4.4 ELISA 
 ELISAs were performed as described previously (Hirakawa et al. 2013). Briefly, 
high-binding assay plates (Corning) were coated with capture antibodies and incubated 
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overnight followed by blocking with 2% BSA (Sigma) in PBS for 1 hour. Plates were 
incubated with lysate diluted 2-fold in 2% BSA, 0.1% Tween-20 PBS for 2 hours, then 
with primary detection antibodies for 2 hours, followed by secondary detection antibodies 
for 30 minutes. Chemiluminescent substrate (Pierce) was added to each plate for 20 
minutes and luminescence measured using a Synergy H1 plate reader. Plates were 
washed four times with a PBS solution containing 0.05% Tween-20 between each 
incubation, and all incubations were done at room temperature. See Supplementary Table 
2.S3 for antibody information. 
2.4.5 Western blot analysis 
 Samples were analyzed by Western blotting as described previously (J. B. 
Fitzgerald et al. 2014). Briefly, clarified cell lysates were boiled in LDS sample buffer 
(Life Technologies) at 95C for 5 minutes, and resolved by electrophoresis on4%–
12%gels (Bio-Rad) using MES running buffer (Bio-Rad). Proteins were transferred to 
nitrocellulose membranes (Life Technologies) using an iBlot device (Life Technologies) 
and membranes were blocked in blocking buffer (LI-COR Biosciences) for 1 hour at 
room temperature. Membranes were probed with primary antibodies in 5% BSA (Sigma), 
0.1% Tween-20 Tris-buffered saline solution (TBS-T) overnight at 4–8C, washed three 
times for 10 minutes in TBS-T, followed by incubation with an anti-rabbit secondary 
antibody (Licor) in 5% milk (Cell Signaling Technology) TBS-T for 45 minutes. After 
three additional 5-minute washes in TBS-T, bands were visualized on a LI-COR 
ODYSSEY CLx imager. Protein bands were quantified using Image Studio (version 
3.1.4) software. 
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2.4.6 Tumor spheroid growth assay 
 Cells were seeded into 96-well nano-culture plates (SCIVAX) at 5,000 cells/well 
and treated following 24-hour growth in media containing 2% FBS. Cell proliferation 
was measured using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega) 
according to the manufacturer's instructions. Luminescence was measured using a 
Synergy H1 plate reader. 
2.4.7 Cell line-derived xenograft studies 
 All animal studies were performed according to the guidelines and approval of the 
Institutional Animal Care and Use Committee. Female Fox Chase SCID Beige mice were 
obtained from Charles River Laboratories and were housed in a pathogen-free 
environment under controlled conditions and received food and water ad libitum. Tumors 
were established by subcutaneous injection of 5 x 106 cells, suspended in 200 mL of 1:1 
Matrigel (Corning): unsupplemented culture media, into one shaven flank of recipient 
mice. Once the average measured tumor volume [calculated according to the formula: p/6 
x (length x width x width)] had reached approximately 400 mm3, mice were randomized 
into groups and treatment was administered as outlined in figure legends. The average 
starting tumor volume per group was equivalent across all groups. Tumor volumes were 
measured twice weekly and statistical significance of mean tumor volume comparisons 
are represented as P values calculated using two-sided, two-sample equal variance t tests. 
For pharmacodynamic analyses, tumors were snap-frozen in liquid nitrogen immediately 
upon extraction, pulverized in a CryoPrep pulverizer (Covaris), and resuspended in 
Tissue Protein Extraction Reagent (Life Technologies) supplemented with phosphatase 
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and protease inhibitor pellets (Roche). Following 30-minute incubation on ice, crude 
tumor lysates were transferred to Qiashredder tubes (Qiagen) and clarified by 
centrifugation (13,000 rpm, 4C) for 10 minutes. 
2.4.8 Patient-derived xenograft studies 
 All animal studies were performed according to the guidelines and approval of the 
Institutional Animal Care and Use Committee. C.B-Igh-1b/lcrTac-Prkdcscid mice were 
obtained from the Roswell Park Comprehensive Cancer Center, Department of 
Laboratory Animals Colony, and were housed in a pathogen-free environment under 
controlled conditions and received food and water ad libitum. Tumors used for the study 
were grown in a donor mouse to a volume of approximately 1,500 mm3. Once the tumor 
reached that volume, the tumor was harvested, cut into 2 mm3 pieces, inserted 
subcutaneously into the right flank of each mouse, and the skin was closed with a wound 
clip. Wound clips were removed 10–14 days post-implantation and tumors were 
measured 1–2 times per week. Once the average measured tumor volume (calculated 
according to the formula: (length x width x height)/2) had reached approximately 400 
mm3, mice were randomized into groups and treatment was administered as outlined in 
the figure legends. The average starting tumor volume per group was equivalent across 
all groups. Tumor volumes were measured twice weekly and statistical significance of 
differences in mean tumor volumes are represented as P values calculated using two-
sided t tests. 
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2.4.9 Histology of tumor tissue 
Metastatic PDAC tumor biopsies were commercially sourced from Avaden 
Biosciences. All tumor tissue samples were formalin fixed, paraffin-embedded, sectioned 
to 4- to 5-mm thickness, and analyzed using the Leica Bond Rx or Ventana Benchmark 
Discovery Platforms. Antibodies used for IHC were as follows: anti-IGF-1R (Ventana, 
G11), anti-ErbB3 (Cell Signaling Technology, D22C5). All IHC-stained specimens were 
scored by a board certified clinical pathologist utilizing the clinical HER2 scoring 
system. Detection of IGF-1 (#313037), IGF-2 (#594367), and HRG (#311187) transcripts 
was performed using the in situ hybridization RNAscope automated assay for the Leica 
Bond Rx (#321100) in accordance with protocols provided by Advanced Cell 
Diagnostics. For each tissue specimen, positive (PPIB, #313907) and negative (DapB, 
#312037) control RNA probes were evaluated to assess tissue quality and assay 
performance alongside scoring of each individual target probe, and scoring was based on 
counting dots per cell. 
2.4.10 Statistical analysis 
 Statistical significance for in vitro results was determined by two-way 
ANOVA/Tukey multiple comparison test using GraphPad Prism software, and statistical 
significance between mean xenograft tumor volumes are represented as P values 
calculated using two-sided, two-sample equal variance t tests using Microsoft Excel 
software. 
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2.5 Results 
2.5.1 IGF1 and HRG potently activate prosurvival signaling in pancreatic cancer 
 To investigate the relative importance of various potential activators of 
PI3K/AKT/mTOR signaling in pancreatic cancer, we determined AKT phosphorylation 
in response to a diverse panel of growth factors in nine PDAC cancer cell lines 
(Supplementary Tables 2.S1 and 2.S2). AKT phosphorylation was determined by 
Western blot analysis (Figure 2.1A) and ELISA (Figure 2.1B). Both analyses showed 
that IGF-1 and/or HRG induced the highest AKT phosphorylation in all cell lines (Figure 
2.1; Supplementary Figure 2.S1). HRG was found to cause the strongest AKT 
activation in all but two of the pancreatic cancer cell lines (PANC-1 and KP-4). Both 
PANC-1 and KP-4 cells were most responsive to IGF-1. Investigation of cell surface 
IGF-1R and ErbB3 receptor expression as measured by quantitative flow cytometry 
revealed a variable expression of IGF-1R and ErbB3 throughout the PDAC cell line panel 
(Figure 2.1C).  
The prevalence of IGF-1R, ErbB3, and their respective ligands (IGF-1, IGF-2, 
and HRG) was investigated in biopsies or surgical resections from pancreatic cancer 
patients with stage IV metastatic disease (Figure 2.2A–O). Expression of IGF-1R and 
ErbB3 in the human samples was investigated by IHC, whereas expression of IGF-1, 
IGF-2, and HRG was investigated by RNA in situ hybridization (RNA-ISH). IGF-1R was 
detectable in 56% of PDAC human tumors, whereas ErbB3 was detectable in 61% of the 
tumors (Figure 2.2P). Detectable levels of either IGF-1R or ErbB3 were measured in 
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83% of the analyzed samples. IGF-1, IGF-2, and HRG mRNA was detected by RNA in 
situ hybridization in 33%, 69%, and 43% of PDAC tumors, respectively (Figure 2.2P). 
Fifty-six percent of samples were found to express IGF-1 or HRG. Coprevalence of IGF-
1R and ErbB3 was found in 39% of samples. Coprevalence of IGF-1 and HRG was found 
in 26% of samples, whereas 40% of samples showed a coprevalence of IGF-2 and HRG. 
All three ligands (IGF-1, IGF-2, and HRG) were detected in 23% of the tested samples. 
Together, these data suggest that IGF-1R and/or ErbB3 signaling pathways may be active 
in many patients with pancreatic cancer. 
2.5.2 Dual IGF-1R/ErbB3 blockade inhibits growth factor–induced prosurvival signaling 
in pancreatic cancer 
 On the basis of the finding that HRG and IGF-1 are strong activators of AKT in 
pancreatic cancer cells, we hypothesized that dual blocking of IGF-1R and ErbB3 can 
effectively inhibit growth factor–mediated prosurvival signaling. We tested the ability of 
the tetravalent bispecific antibody istiratumab to inhibit AKT activation in nine 
pancreatic cancer cell lines in response to stimulation with IGF-1, HRG, or costimulation 
with both IGF-1 and HRG. Istiratumab significantly inhibited AKT activation in response 
to IGF-1 and HRG costimulation in all cell lines (Figure 2.3A; Supplementary Figure 
2.S2). This was the case both when cells were exposed to istiratumab prior to ligand 
(Figure 2.3A) and when cells were exposed to ligand prior to the antibody 
(Supplementary Figure 2.S2). Of note, istiratumab also inhibited IGF-1- and HRG-
induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS 
mutations, such as HPAF-II (KRAS G12V) and CFPAC-1 (KRAS G12D). 
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To determine the impact of the bispecific antibody format, we compared AKT 
phosphorylation in HPAF-II and CFPAC-1 cells in the presence of istiratumab or a 
mixture of IGF-1R- and ErbB3-targeting monospecific antibodies. Our studies showed 
that 500 nmol/L istiratumab was superior in inhibiting in vitro AKT phosphorylation, 
compared with the mixture of 500 nmol/L IGF-1R- and 500 nmol/L ErbB3-targeting 
mAbs (Figure 2.3B). Mechanistic analyses revealed that istiratumab decreased IGF-1R 
and/or ErbB3 protein levels in nearly all nine pancreatic cancer cell lines tested (Figure 
2.4A). Moreover, istiratumab decreased IGF-1R and ErbB3 to a greater extent than either 
IGF-1R- or ErbB3-targeting monospecific antibodies or their mixture in multiple cell 
lines (Figures 2.4B and C). Monospecific anti-IGF-1R antibodies caused a 
compensatory increase in ErbB3 protein expression in Capan-2 cells (Figure 2.4C), 
whereas anti-ErbB3 antibodies caused a compensatory increase in IGF-1R protein levels 
in Capan-2, CFPAC-1, and PANC-1 cells (Figure 2.4B). Immunoprecipitation analysis 
of CFPAC-1 cell lysates revealed that treatment with istiratumab induced IGF-1R and 
ErbB3 receptor ubiquitination within 20 minutes, suggesting that istiratumab rapidly 
induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway 
(Supplementary Figure 2.S3). 
2.5.3 Dual IGF-1R/ErbB3 blockade prevents IGF-1 and HRG from desensitizing 
pancreatic cancer cells to gemcitabine or paclitaxel 
 The effects of IGF-1R/ErbB3 signaling on the activity of clinically relevant 
chemotherapies in pancreatic cancer were tested in vitro. Adding the growth factors IGF-
1 and HRG reduced tumor cell sensitivity to paclitaxel or gemcitabine in spheroid growth 
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assays (Figure 2.5A and B; Supplementary Figure 2.S4). On the basis of our results 
showing that dual IGF-1R/ErbB3 blockade with istiratumab inhibits growth factor–
induced activation of prosurvival signaling, we investigated whether istiratumab could 
resensitize pancreatic cancer cells to chemotherapy in the presence of IGF-1 and HRG. 
Our studies showed that the addition of istiratumab resensitized pancreatic cancer cells to 
paclitaxel or gemcitabine (Figure 2.5A and B; Supplementary Figure 2.S4). Together, 
these data suggest that the IGF-1R and ErbB3 pathways are potential routes for escape of 
pancreatic cancer cells from gemcitabine and paclitaxel activity and that addition of 
istiratumab may restore sensitivity to these chemotherapy agents.  
To determine potential interactions between chemotherapy and IGF-1R/ErbB3 
pathways, we investigated the effects of gemcitabine and paclitaxel on IGF-1R and 
ErbB3 expression, as well as AKT phosphorylation. Both gemcitabine and paclitaxel 
promoted early (at 1-hour posttreatment) upregulation of IGF-1R and ErbB3 in CFPAC-1 
cells (Figure 2.5C and D). Paclitaxel induced an increase of AKT phosphorylation in the 
presence of IGF-1 or HRG (Figure 2.5 E and F). Gemcitabine also promoted a 
significant enhancement of AKT phosphorylation in the presence of HRG (Figure 2.5F). 
Addition of istiratumab to either gemcitabine or paclitaxel in the presence of IGF-1 or 
HRG led to a striking decrease of pAKT (Figure 2.5E and F). The changes in AKT 
phosphorylation correlated with changes in caspase-3/7 activity. IGF-1 and HRG led to a 
significant decrease of caspase-3/7 activity when added to paclitaxel chemotherapy in 
vitro (Figure 2.5 G and H). In the presence of IGF-1 and HRG, addition of istiratumab 
to gemcitabine or paclitaxel resulted in a significant increase of caspase activity (Figure 
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2.5G and H) as compared with chemotherapy. Similar to observations with CFPAC-1, a 
chemotherapy-mediated increase in expression of IGF-1R and/or ErbB3 was measured in 
other pancreatic cancer cell lines (Supplementary Figure 2.S5). 
These data demonstrate that treatment with gemcitabine and paclitaxel may alter 
the signaling network of pancreatic cancer cells in a manner that enhances IGF-1R and 
ErbB3 expression and subsequent AKT activation in response to IGF-1 and HRG. The 
data also suggest that istiratumab may potently inhibit AKT activation, resensitizing 
pancreatic cancer cells to chemotherapy and promoting apoptosis. 
2.5.3 Dual IGF-1R/ErbB3 blockade potentiates the antitumor activity of chemotherapy in 
vivo 
 We tested whether adding istiratumab to gemcitabine and nab-paclitaxel increases 
the antitumor activity of chemotherapy in KRAS-mutant HPAF-II and CFPAC-1 cell 
line–derived xenograft models in vivo. Istiratumab monotherapy resulted in only a slight 
delay in tumor growth, whereas treatment with gemcitabine and nab-paclitaxel resulted in 
regression of CFPAF-I and strong growth delay of HPAF-II tumors (Figure 2.6A and 
B). Addition of istiratumab to chemotherapy resulted in striking tumor regression in both 
models (Figure 2.6A and B). Complete tumor eradication was detected in 40% and 20% 
of mice with HPAF-II and CFPAC-1 tumors, respectively, when istiratumab was added 
to chemotherapy. Pharmacodynamic analyses of CFPAC-1 and HPAF-II tumors showed 
that addition of istiratumab to gemcitabine and nab-paclitaxel decreased levels of IGF-1R 
and ErbB3 (Figure 2.6C and D). Moreover, the triple combination decreased 
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phosphorylation of ribosomal protein S6 and eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1), both downstream signaling of AKT, compared to the 
gemcitabine/nab-paclitaxel treatment (Figures 2.6E–F). In vivo istiratumab-induced 
receptor downregulation was confirmed by IHC in both models (Figure 2.6G). The in 
vivo pharmacodynamic effects of istiratumab over time were further investigated in 
HPAF-II xenograft tumor models. Here, tumors were harvested 16, 48, and 72 hours after 
a single treatment with istiratumab in combination with gemcitabine/nab-paclitaxel, and 
compared to tumors treated with gemcitabine/nab-paclitaxel alone. Western blot analysis 
demonstrated that the addition of a single dose of istiratumab to the dual chemotherapy 
regimen resulted in reduction of IGF-1R and ErbB3 at all time points (Supplementary 
Figure 2.S6). 
 The in vivo activity of the dual IGF-1R/ErbB3 inhibitor istiratumab was also 
investigated in a PDX model of human pancreatic cancer (PDX #14244). Istiratumab 
monotherapy significantly delayed tumor growth, compared to control animals (Figure 
2.6H). Moreover, the addition of istiratumab improved the activity of gemcitabine/nab-
paclitaxel chemotherapy (Figure 2.6H). Although the magnitude of the impact of 
istiratumab upon chemotherapy was smaller compared to the CFPAC-1 and HPAF-II 
models, the improvement in tumor growth/response when istiratumab was added to 
chemotherapy was significant for all time points. Because the strong response of the 
14244 PDX model to chemotherapy alone, treatment was stopped after three treatment 
cycles (week 3) and tumor regrowth posttreatment discontinuation was monitored over 
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time. Of note, tumor regrowth was significantly slower in the animals previously treated 
with chemotherapy plus istiratumab, compared to chemotherapy alone (Figure 2.6H). 
2.6 Discussion 
 Poor clinical outcomes underscore the need to develop novel therapies for the 
treatment of pancreatic cancer. To this end, a better understanding of resistance 
mechanisms to standard-of care treatment is essential. In recent years, RTKs have been 
identified as critical effectors of pancreatic cancer progression (Preis and Korc 2010). 
Among them, the IGF-1R pathway has been identified as promoting prosurvival signaling 
and reducing the activity of cytotoxic therapies (Kawanami et al. 2012)(X. Tian et al. 
2013)(Ireland et al. 2016). However, scientific evidence suggests that multiple signaling 
pathways are dysregulated in pancreatic cancer, limiting the potential of single pathway 
inhibitors to control disease progression (Preis and Korc 2010)(Jones et al. 2008). Here, 
we show that the HRG/ErbB3 axis is critically involved in pancreatic cancer and that 
resistance to IGF-1R signaling inhibition may be due to compensatory activation of 
ErbB3 downstream signaling. 
In contrast to other ErbB family members, ErbB3 lacks a functioning kinase 
domain (Jura et al. 2009). The growth factor heregulin promotes heterodimerization of 
ErbB3 with other RTKs and subsequent downstream signaling activation (Wallasch et al. 
1995). ErbB3 heterodimers are considered potent inducers of the prosurvival PI3K/AKT 
pathway, promoting tolerance/resistance to various standard-of-care therapies, such as 
PI3K signaling inhibitors, cytotoxic chemotherapies, and hormonal therapies (Schoeberl 
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et al. 2017). ErbB3-mediated resistance involves protein overexpression through 
increased ERBB3 transcription and/or activation through increased autocrine or paracrine 
HRG signaling, as well as ligand-independent activation by other RTKs (Garrett et al. 
2011)(Engelman et al. 2007)(Sergina et al. 2007). Ligand-independent activation of 
ErbB3 may also be promoted by mutations in the extracellular domain of the protein 
(Arteaga and Engelman 2014). Recent evidence suggests that the tumor 
microenvironment can cause de novo resistance to PI3K signaling inhibitors by activating 
the HRG/ErbB3 axis (Kodack et al. 2017). Using an unbiased in vitro growth factor 
screen on nine different pancreatic cancer cell lines, we show that HRG is a dominant 
activator of PI3K/AKT signaling in PDAC, in addition to IGF-1. Moreover, by IHC and 
ISH we observed that ErbB3 and/or HRG are expressed in a significant proportion of 
samples from patients with metastatic pancreatic cancer. These results are consistent with 
findings from previous studies, which showed that ErbB3 is involved in pancreatic cancer 
tumorigenesis (J Spencer Liles et al. 2010). In addition, previous tumor 
microenvironment studies revealed that pancreatic cancer-associated fibroblasts can 
secrete heregulin, and promote the proliferation of PDAC cells by activation of ErbB3 
and AKT signaling (J. S. Liles et al. 2011). 
Understanding the interactions between multiple signaling pathways is critical for 
the identification of effective therapeutic strategies in pancreatic cancer. This has become 
increasingly clear as promising monospecific targeted therapies have demonstrated 
disappointing results in clinical trials (McCaffery et al. 2013)(Philip et al. 2014). It has 
been hypothesized that these therapies may be too narrowly focused since there are 
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redundant, parallel signaling pathways that allow tumor cells to escape treatment. 
Understanding the interplay between multiple oncogenic signaling pathways in a specific 
tumor type is essential for the design of more effective, multitargeted therapeutic 
regimens. Our study provides evidence for an interplay between IGF-1R and ErbB3 in 
pancreatic cancer. Consistent with previous findings (J. B. Fitzgerald et al. 2014)(J. 
Fitzgerald and Lugovskoy 2011), we show that ErbB3 upregulation may compensate for 
IGF-1R blockade and vice versa. Moreover, our data suggest that standard-of-care 
chemotherapies, such as gemcitabine and paclitaxel, increase the expression and 
activation of both IGF-1R and ErbB3 in pancreatic cancer cells, rendering them tolerant 
to cytotoxic therapies. An association between decreased overall survival in stage IV 
metastatic pancreatic cancer patients and coexpression of IGF-1R and ErbB3 has been 
reported (Wang-Gillam et al. 2015). Together, these findings point to ErbB3 as a 
potentially critical mediator of tumor growth and resistance to both IGF-1R inhibitors and 
chemotherapy in pancreatic cancer. 
Based on the role of ErbB3 in therapy tolerance/resistance, we hypothesized that 
co-inhibition of IGF-1R and ErbB3 is necessary to achieve sustained suppression of 
pancreatic tumor growth. This hypothesis was tested using istiratumab, a fully human 
bispecific tetravalent IGF-1R- and ErbB3-targeting antibody, which is composed of a 
monoclonal IgG1 antibody, engineered to contain two single-chain Fv fragments at the 
carboxy termini of the heavy chain (J. B. Fitzgerald et al. 2014)(J. Fitzgerald and 
Lugovskoy 2011)(Xu et al. 2013). Istiratumab possesses four high-affinity binding sites 
and has two modes of action: (i) it blocks IGF-1, IGF-2, and HRG binding to their 
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receptors; and (ii) it induces degradation of receptor complexes containing IGF-1R and 
ErbB3 (J. B. Fitzgerald et al. 2014)(Xu et al. 2013). Our data indicate that the addition of 
istiratumab to the gemcitabine and (nab-)paclitaxel regimen creates a potent therapeutic 
opportunity in a growth factor positive setting by blocking ligand induced IGF-1R and 
ErbB3 signaling and preventing chemotherapy-mediated upregulation of targeted 
receptors. Importantly, growth factor-induced chemoresistance was antagonized by 
istiratumab regardless of activating KRAS mutations, highlighting the importance of 
PI3K/AKT signaling blockade in pancreatic cancer. The choice of the bispecific drug 
versus monospecific antibodies was based on previous experimental and modeling 
analyses, which indicated a stronger suppression of AKT phosphorylation for the 
bispecific inhibitor, compared to a mixture of monospecific anti-IGF-1R and anti-ErbB3 
antibodies at equimolar concentrations, a result that was confirmed in pancreatic cancer 
in the present study (J. B. Fitzgerald et al. 2014). 
The in vivo activity of the dual IGF-1R/ErbB3 inhibitor alone was modest and 
varied in the different preclinical models. This could be due to variable levels of intrinsic 
tumor dependency to IGF-1R/ErbB3 pathway signaling. In all models, however, 
istiratumab enhanced the antitumor activity of chemotherapy. Our data suggest that this is 
likely due to chemotherapy-mediated alterations of the IGF-1R/ErbB3 pathways, such as 
chemotherapy induced increase of IGF-1R and/or ErbB3 expression and activation in the 
presence of their ligands. The fact that istiratumab seems to be more effective when 
combined with chemotherapy could, however, also be explained by chemotherapy-
mediated changes in the tumor microenvironment that facilitate the delivery of the 
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antibody. Pancreatic ductal adenocarcinomas are characterized by high levels of 
desmoplasia, which affects the physical properties of tumors and results in intratumor 
vasculature collapse (Stylianopoulos and Jain 2013)(Jain, Martin, and Stylianopoulos 
2014). Various drugs, including taxane-based chemotherapies, have been shown to 
alleviate physical forces in tumors leading to vessel deformation and improved perfusion 
and drug delivery (Griffon-Etienne et al. 1999)(Chauhan et al. 2013)(Olive et al. 
2010)(Provenzano et al. 2012). Therefore, the activity of istiratumab could be also 
potentiated by chemotherapy-mediated cell-killing that alters the tumor 
mechanopathology and improves the delivery and tumor penetration of the antibody. 
The failure of monospecific IGF-1R blocking antibodies in clinical trials may 
have various explanations: (i) monospecific antibodies are unable to effectively inhibit 
IGF-1R signaling in the tumor; (ii) they are unable to inhibit the compensatory ErbB3 
pathway, which reactivates AKT signaling; and (iii) they may not have been administered 
to the right patient population. Istiratumab degrades IGF-1R levels to a greater extent 
than monospecific anti-IGF-1R antibodies and prevents compensatory upregulation of 
ErbB3 in response to the IGF-1R blockade. Moreover, istiratumab blocks HRG signaling, 
which seems to be a prominent, previously overlooked activator of AKT in pancreatic 
cancer cells. Interestingly, IGF-1R and ErbB3 expression was not consistently elevated in 
the cell lines most responsive to IGF-1 and/or HRG, suggesting receptor expression alone 
may not be predictive of active signaling. This is consistent with previous studies 
showing that IGF-1R levels in patient tumor samples do not correlate with response to 
IGF-1R blockers (Cao et al. 2014). Of note, both IGF-1 and HRG desensitize tumor cells 
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to gemcitabine and paclitaxel suggesting that patients with pancreatic tumors that have 
active IGF-1 and/or HRG signaling are more likely to respond to an IGF-1R and ErbB3 
multitargeted therapy. This creates a strong rationale for using ligand levels as 
biomarkers in clinical trials of istiratumab. Based on these findings, a double-blind 
placebo-controlled phase II study of istiratumab in combination with nab-paclitaxel plus 
gemcitabine versus nab-paclitaxel and gemcitabine alone in front-line metastatic 
pancreatic cancer patients with high free IGF-1 serum levels was initiated and is currently 
ongoing (www.clinicaltrials.gov; ID: NCT02399137). In addition to prospective free 
IGF-1–based patient selection, a co-primary endpoint in the phase II proof-of-concept 
trial is PFS activity of istiratumab with gemcitabine/nab-paclitaxel in patients with both 
high free IGF-1 serum levels and heregulin-positive tumors. 
In summary, our results show that the HRG/ErbB3 axis is critical to pancreatic 
cancer progression and therapeutic resistance to IGF-1R inhibition. Both IGF-1R and 
ErbB3 can serve as drivers of tumor growth and resistance/tolerance to standard-of-care 
chemotherapy. These data highlight that pancreatic tumors exploit both pre-wired and 
acquired mechanisms of activating the IGF-1R/ErbB3/AKT signaling axis to escape the 
cytotoxic action of standard-of-care therapies. Our findings support current clinical 
investigation of istiratumab in combination with gemcitabine and nab-paclitaxel in 
subsets of pancreatic cancer patients whose disease is characterized by high expression of 
IGF-1R and ErbB3 ligands. 
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Figure 2.1: IGF-1 and HRG induce AKT phosphorylation in pancreatic cancer cells. 
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A, Nine pancreatic cancer cell lines were serum-starved for 24 hours and then treated for 
15 minutes with 100 ng/mL of each growth factor. Cell lysates were collected, and pAKT 
S473 was determined by Western blot analysis (A) or ELISA (B). For ELISA, ng/mL 
pAKT was control-subtracted and maximum-normalized within each cell line. Heatmap 
data represent mean normalized values of duplicates from two separate experiments. C, 
Surface IGF-1R and ErbB3 receptor levels were quantified in nine human pancreatic cell 
lines using quantitative flow cytometry. Data represent number of receptors/cell from two 
separate experiments.  
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Figure 2.2: Expression of IGF-1R, ErbB3, and their ligands (IGF-1, IGF-2, and 
HRG) in human metastatic pancreatic cancer tissue. 
 
 
Protein % Prevalence
IGF-1R (n=43) 56%
ErbB3 (n=44) 61%
IGF-1 (n=42) 33%
IGF-2 (n=42) 69%
HRG (n=42) 43%
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A–O, Representative images of IGF-1R and ErbB3 IHC (diffuse brown staining) and 
representative images of IGF-1, IGF-2, and HRG RNA in situ hybridization (RNA-ISH, 
punctate dots in cells) from pancreatic cancer tissues are shown next to normal control 
tissues. Positive and negative controls include normal breast tissue (A–C), normal liver 
tissue (D–F), normal pancreas tissue (G–H, J), and normal kidney tissue (I). P, A panel of 
metastatic pancreatic tumors was profiled for expression of IGF-1R, ErbB3, and their 
respective ligands. IHC specimens were scored by a pathologist using the clinical HER2 
scoring system criteria (IHC positivity is considered ≥1+ in 10% of tumor cells), and ISH 
specimens were scored by quantifying dots/cell (ISH positivity is considered ≥1 dot/cell 
in at least 10% of tumor or stromal cells).  
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Figure 2.3: Dual IGF-1R/ErbB3 blockade inhibits IGF-1– and HRG-induced AKT 
phosphorylation in human pancreatic cancer cell lines in vitro. 
 
A, Istiratumab inhibits dual growth factor–induced pAKT across the entire pancreatic 
cancer panel. Nine human pancreatic cancer cell lines were pretreated for 24 hours with 
vehicle or 500 nmol/L istiratumab, then stimulated for 15 minutes with a mixture of 50 
nmol/L IGF-1 and 5 nmol/L HRG. Following treatment, cell lysates were collected and 
pAKT was measured by ELISA. Bars represent mean + SD of duplicates and are 
representative of a minimum of two separate experiments. B, Istiratumab inhibits dual 
growth factor–induced AKT phosphorylation stronger than a mixture of anti-IGF-1R and 
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anti-ErbB3 monospecific antibodies. CFPAC-1 and HPAF-II cells were pretreated for 24 
hours with a dilution series starting at 500 nmol/L of either istiratumab (red) or a mixture 
of anti-IGF-1R and anti-ErbB3 antibodies (black), then stimulated for 15 minutes with a 
mixture of 50 nmol/L IGF-1 and 5 nmol/L HRG. Following treatment, cell lysates were 
collected and pAKT was measured by ELISA. pAKT signal is control-subtracted and 
normalized to the IGF-1 + HRG control for each cell line. Line graphs are representative 
of the mean of two separate experiments, and are plotted as mean + SD of ELISA 
duplicates.  
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Figure 2.4: Istiratumab induces receptor degradation stronger than anti-IGF-1R 
and anti-ErbB3 monospecific antibodies. 
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A, Western blot analysis of ErbB3 and IGF-1R from cell lysates of nine pancreatic cancer 
cell lines after treatment in the absence or presence of istiratumab. B and C, Serum-
starved pancreatic cancer cells were treated for 24 hours with vehicle, 500 nmol/L 
istiratumab, 500 nmol/L anti-IGF-1R antibody, or 500 nmol/L anti-ErbB3 antibody. 
Following treatment, cell lysates were harvested and total IGF-1R and ErbB3 levels were 
measured by ELISA. Bar graphs represent the mean + SD of ELISA duplicates and are 
representative of a minimum of two separate experiments. ns, not significant; **, P < 
0.005; ***, P < 0.001; ****, P < 0.0001.  
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Figure 2.5: Istiratumab restores activity of chemotherapy in the presence of IGF-1 
and HRG. 
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A and B, Serum-starved BxPC-3, Capan-2, CFPAC-1, and HPAF-II cell spheroids 
propagated in nanoculture plates were treated for 4 days with either paclitaxel (A) or 
gemcitabine (B) over a dilution series, in the presence of vehicle (blue), a mixture of 50 
nmol/L IGF-1 and 10 nmol/L HRG (black), or a mixture of 50 nmol/L IGF-1, 10 nmol/L 
HRG, and 1 μmol/L istiratumab (red). Relative cell proliferation was assessed by 
CellTiter-Glo assay. Line graph data are expressed in relative light units (RLU) and are 
normalized to untreated vehicle (mean + SEM). C and D, Treatment with gemcitabine or 
paclitaxel upregulates IGF-1R and ErbB3 expression in CFPAC-1 pancreatic cancer 
cells. CFPAC-1 cells were treated for 1 hour with 1 μmol/L gemcitabine or 100 nmol/L 
paclitaxel. Cell lysates were collected, and IGF-1R and ErbB3 were quantified by 
ELISA. Bar graphs represent the mean + SD of duplicates and are representative of a 
minimum of two separate experiments. E and F, Istiratumab inhibits chemotherapy-
enhanced, growth factor–induced AKT phosphorylation. CFPAC-1 cells were pretreated 
for 24 hours with either vehicle, 100 nmol/L paclitaxel (Pac), 1 μmol/L gemcitabine 
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(Gem), 500 nmol/L istiratumab, alone or in combination as indicated, and then stimulated 
for 15 minutes with 50 nmol/L IGF-1 or 5 nmol/L HRG. Cell lysates were collected, and 
changes in pAKT were measured by ELISA. Bar graphs are plotted as the mean + SD of 
duplicates and are representative of a minimum of two separate experiments. G and H, 
Isitratumab potentiates chemotherapy-induced caspase-3/7 activity in the presence of 
IGF-1 and HRG. Serum-starved CFPAC-1 cells grown with the IncuCyte Caspase-3/7 
Green Apoptosis Assay Reagent in 96-well plates were treated in octuplicate for 16 hours 
with 100 nmol/L paclitaxel (Pac), 1 μmol/L gemcitabine, 500 nmol/L istiratumab, 50 
nmol/L IGF-1, or 5 nmol/L HRG as indicated, then caspase 3/7 activity was assessed in 
the IncuCyte live cell imager. ns, not significant; *, P < 0.05; **, P < 0.005; ***, P < 
0.001; ****, P < 0.0001.  
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Figure 2.6: Istiratumab enhances in vivo activity of chemotherapy in pancreatic 
cancer xenograft models. 
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A and B, Addition of istiratumab to gemcitabine/nab-paclitaxel chemotherapy resulted in 
increased CFPAC-1 (A) and HPAF-II (B) xenograft tumor regression. Mice were treated 
by intraperitoneal injection with vehicle (black), istiratumab monotherapy (30 mg/kg, 
every 3 days; red), the dual combination of gemcitabine (10 mg/kg for CFPAC-1 and 40 
mg/kg for HPAF-II, every 6 days) and nab-paclitaxel (10 mg/kg, every 3 days; blue), or 
the triple combination of gemcitabine, nab-paclitaxel plus istiratumab as dosed for the 
monotherapy (purple). Error bars represent the SEM (N = 10 mice, P < 0.002 for 
gemcitabine/nab-paclitaxel vs. istiratumab/gemcitabine/nab-paclitaxel from day 13 
onward in both models). C–F, Dual IGF-1R/ErbB3 inhibition with istiratumab induces 
degradation of IGF-1R and ErbB3 and inhibits downstream prosurvival signaling in 
mouse xenograft pancreatic tumors. CFPAC-1 (C and E) and HPAF-II (D and F) end-of-
study tumors were harvested 24 hours after final drug administration. Tumor lysates were 
immunoblotted for total IGF-1R and ErbB3 (C and D), or pS6 (S240/244) and p4E-BP1 
(S65; E and F). Bars shown in red represent samples treated with istiratumab. Bar graphs 
represent the mean signal + SD (N = 4 mice), normalized to beta-actin. *, P < 0.05. G, 
Mice bearing CFPAC-1 and HPAF-II xenograft tumors were treated with istiratumab (30 
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mg/kg, i.p.), and tumors were harvested 24 hours after treatment (top two rows). 
Formalin-fixed, paraffin-embedded tumor samples were probed for IGF-1R or ErbB3 
receptor expression by IHC. Images were acquired at 40× magnification. H, Addition of 
istiratumab to gemcitabine/nab-paclitaxel chemotherapy resulted in increased efficacy in 
pancreatic PDX model #14244. Mice were treated with vehicle (black), istiratumab 
monotherapy (30 mg/kg, twice weekly; red arrows), the dual combination of gemcitabine 
(25 mg/kg, weekly), and nab-paclitaxel (15 mg/kg, weekly; blue arrows), or the triple 
combination of gemcitabine and nab-paclitaxel (as dosed for the monotherapies) plus 
istiratumab (purple) for 3 weeks. Error bars represent the SEM (N = 8 mice). 
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Figure 2.S1: IGF-1 and HRG induce strongest AKT phosphorylation in pancreatic 
cancer cells.  
 
Nine pancreatic cancer cell lines were serum-starved for 24 hours and then treated for 15 
minutes with 100 ng/mL of one of fourteen growth factors. Cell lysates were collected 
and AKT S473 phosphorylation levels were measured by ELISA. Non-normalized data 
from heatmap in Figure 1B.    
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Figure 2.S2: Istiratumab inhibits growth factor-induced AKT phosphorylation 
across a pancreatic cancer cell line panel. 
 
52 
 
Nine pancreatic cancer cell lines were serum-starved for 24 hours in the presence of 5nM 
HRG, 50nM IGF1, or their combination, and then treated for 24 hours with 500nM 
istiratumab. Cell lysates were collected and AKT S473 phosphorylation levels were 
measured by western blot. 
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Figure 2.S3: Istiratumab induces ubiquitination of IGF-1R and ErbB3.  
 
Serum-starved CFPAC-1 cells were pre-treated with 1 μM epoxomicin for 2 hours to 
allow for accumulation of ubiquitinated proteins, followed by treatment with 500 nM 
istiratumab or vehicle for 20 minutes. Cell lysates were immunoprecipitated (IP) with an 
IGF-1R (top panel) or ErbB3 (bottom panel) antibody, resolved by SDS-PAGE, and 
immunoblotted (IB) for IGF-1R, ErbB3, or ubiquitin (Ub). 
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Figure 2.S4: Istiratumab restores activity of chemotherapy in the presence of IGF-1 
and HRG.  
 
(A,B) Serum-starved AsPC1, KP-4, PANC-1, SU.86.86, and SW1990 cell spheroids 
propagated in nano-culture plates were treated in triplicate for 4 days with various 
concentrations of either (A) paclitaxel or (B) gemcitabine, in the presence of vehicle 
(blue), a mixture of 50 nM IGF-1 and 10 nM HRG (black), or a mixture of 50 nM IGF-1, 
10 nM HRG, and 1 μM istiratumab (red). Relative cell proliferation was assessed by 
CellTiter-Glo assay. Line graph data are expressed in relative light units (RLU) and are 
normalized to untreated vehicle control (mean + SEM). 
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Figure 2.S5: Gemcitabine and paclitaxel can upregulate IGF-1R and ErbB3 in 
pancreatic cancer cells.  
 
Cells were treated for one hour with 1 μM gemcitabine or 100 nM paclitaxel. Cell lysates 
were collected and IGF-1R or ErbB3 protein levels were quantified by ELISA. Cells 
were also treated in the presence of istiratumab (red). Istiratumab decreased levels of 
receptor expression in various pancreatic cancer cell lines. Bar graphs represent the mean 
+ SD of duplicates and are representative of a minimum of two separate experiments. 
“ns” not significant, * p<0.05, ** p<0.005, *** p<0.001, **** p<.0001. 
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Figure 2.S6: In vivo expression of IGF-1R and ErbB3 in HPAF-II tumors over time.  
 
Total IGF-1R (left) and ErbB3 (right) protein levels were quantified in tumors harvested 
at 16, 48 and 72 hours post istiratumab treatment by western blotting. Bars shown in red 
represent samples treated with istiratumab. Istiratumab significantly decreased expression 
levels of IGF-1R and ErbB3 at all time points compared to control (p<0.05). Bar graphs 
represent mean signal + SD (N = 4 mice), normalized to beta-actin *p < 0.05. 
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Table 2.S1: 
Cell 
Line 
Source Cat # KRAS 
mutatio
n 
5% 
CO2 
Media 
Type 
Media 
Vendor 
Media 
sup 
AsPC-1 ATCC CRL-
1682 
G12D yes RPMI Life 
Tech 
P/S, 
10% 
FBS 
BxPC-3 ATCC CRL-
1687 
Wild-
type 
yes RPMI Life 
Tech 
P/S, 
10% 
FBS 
Capan-2 ATCC HTB-80 G12V yes McCoy’
s 5A 
Life 
Tech 
P/S, 
10% 
FBS 
CFPAC-
1 
ATCC CRL-
1918 
G12V yes IMDM Life 
Tech 
P/S, 
10% 
FBS 
HPAF-II ATCC CRL-
1997 
G12D yes EMEM ATCC P/S, 
10% 
FBS 
KP-4 Riken JCRB01
82 
G12D yes DMEM:
F12 
Life 
Tech 
P/S, 
10% 
FBS 
PANC-1 ATCC CRL-
1469 
G12D yes DMEM Life 
Tech 
P/S, 
10% 
FBS 
SU.86.8
6 
ATCC CRL-
1837 
G12D yes RPMI Life 
Tech 
P/S, 
10% 
FBS 
SW 
1990 
ATCC CRL-
2172 
G12D no L-15 Life 
Tech 
P/S, 
10% 
FBS 
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Table 2.S2: 
Ligand Abbreviation Vendor Cat # 
rh-Betacellulin BTC PeproTech 100-50 
rh-Epidermal Growth Factor EGF PeproTech AF-100-15 
rh-Epiregulin EPR PeproTech 100-04 
rh-Fibroblast Growth Factor-acidic FGF-1 PeproTech 100-17A 
rh-Fibroblast Growth Factor-basic FGF-2 PeproTech 100-18B 
rh-Hepatocyte Growth Factor HGF PeproTech 100-39 
rh-Heregulin-Beta-1 HRG R&D 396-HB-050 
rh-Insulin-like Growth Factor 1 IGF-1 R&D 291-G1-200 
rh-Insulin-like Growth Factor 2 IGF-2 Peprotech 100-12 
rh-Insulin INS Sigma I9278 
rh-beta-Nerve Growth Factor NGFB PeproTech 450-01 
rh-Platelet-Derived Growth Factor-
BB 
PDGF PeproTech 100-14B 
rh-Stem Cell Factor SCF PeproTech 300-07 
rh-Vascular Endothelial Growth 
Factor 
VEGF PeproTech 100-20 
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Table 2.S3: 
Antibody Use Vendor Cat # 
Anti-Akt/PKB 
Antibody, PH Domain, 
clone SKB1 
ELISA capture Upstate 05-591MG 
Human ErbB3 MAb 
(Clone 66223) 
ELISA capture, 
Immunoprecipitation 
R&D Systems MAB3481 
Human IGF-I R MAb 
(Clone 33255)  
ELISA capture R&D Systems MAB391 
Phospho-Akt (Ser473) 
(587F11) Mouse mAb 
(Biotinylated) 
ELISA detection Cell Signaling 
Technologies 
5102 
Human ErbB3 
Biotinylated MAb 
(Clone 66201) 
ELISA detection R&D Systems BAM348 
IGF-I Receptor β 
(D23H3) XP® Rabbit 
mAb 
ELISA detection, 
Immunoprecipitation, 
Primary Immunoblot 
Cell Signaling 
Technologies 
9750 
Streptavidin-HRP ELISA secondary 
detection 
R&D Systems DY998 
Anti-rabbit IgG, HRP-
linked Antibody 
ELISA secondary 
detection 
Cell Signaling 
Technologies 
7074 
HER3/ErbB3 (D22C5) 
XP® Rabbit mAb 
Primary Immunoblot Cell Signaling 
Technologies 
12708 
Phospho-S6 
Ribosomal Protein 
(Ser240/244) (D68F8) 
XP® Rabbit mAb 
Primary Immunoblot Cell Signaling 
Technologies 
5364 
Phospho-4E-BP1 
(Ser65) Antibody 
Primary Immunoblot Cell Signaling 
Technologies 
9451 
β-Actin (D6A8) Rabbit 
mAb 
Primary Immunoblot Cell Signaling 
Technologies 
8457 
Ubiquitin Antibody Primary Immunoblot Cell Signaling 
Technologies 
3933 
IRDye® 800CW Goat 
anti-Rabbit IgG (H + 
L) 
Secondary Immunoblot LiCor 926-32211 
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CHAPTER 3: DUAL TARGETING OF IGF-1R AND ERBB3 AS A POTENTIAL 
THERAPEUTIC REGIMEN FOR OVARIAN CANCER 
3.1 Abstract 
 Therapeutically targeting receptor tyrosine kinases has proven to be paramount to 
overcoming chemotherapy resistance in several cancer indications, improving patient 
outcomes. Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epidermal Growth 
Factor Receptor 3 (ErbB3) have been implicated as two such drivers of resistance, 
however their simultaneous role in ovarian cancer chemotherapy resistance remains 
poorly elucidated. The aim of this work is to determine the effects of dual IGF-1R/ErbB3 
inhibition on ovarian cancer cell signaling, growth, and in vivo efficacy. Assessment of in 
vitro chemotherapy response across a panel of ovarian cancer cell lines revealed that 
increased IGF-1R cell surface expression correlates with decreased sensitivity to 
chemotherapy, and that growth induced by IGF-1R and ErbB3 ligands is blocked by the 
tetravalent bispecific antibody targeting IGF-1R and ErbB3, istiratumab. In vitro 
chemotherapy treatment increased ovarian cancer cell line capacity to activate 
prosurvival PI3K signaling in response to ligand, which could be prevented with 
istiratumab treatment. Furthermore, in vivo efficacy of standard of care chemotherapies 
using a xenograft model of ovarian cancer was potentiated with istiratumab. Our results 
suggest a role for IGF-1R and ErbB3 in driving chemotherapy resistance of ovarian 
cancer. 
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3.2 Introduction 
Ovarian cancer is the fifth most common malignancy in women representing a 
leading cause of cancer-related death (R. Siegel et al. 2014). In 2018 more than 22,000 
women in the USA were diagnosed with ovarian cancer, with 14,000 ovarian-cancer 
related deaths (Torre et al. 2018). Due to late onset of symptoms more than two thirds of 
patients are diagnosed with locally advanced or metastatic stage disease (Torre et al. 
2018), and established therapeutic regimens include combinations of platinum- and 
taxane-based chemotherapies (NCCN Guidelines). Initial treatment responses are 
common, however, they are usually followed by disease recurrence. This underscores the 
urgent need for a deeper understanding of ovarian cancer pathophysiology and the 
development of novel therapeutic approaches.   
 Receptor tyrosine kinases may have a critical role in the pathophysiology of 
ovarian cancer. Among these, insulin growth factor 1 receptor (IGF-1R) is implicated in 
development, progression, metastasis and chemotherapy resistance of ovarian cancer 
(Liefers-Visser et al. 2017). IGF-1R, its activating ligands (IGF-1, IGF-2), as well as 
regulating insulin growth factor binding proteins (IGFBP), are expressed in ovarian 
malignancies, supporting the hypothesis that IGF-1R signaling might be a promising 
therapeutic target (Yee et al. 1991)(Resnicoff et al. 1993). As a result, strategies to inhibit 
IGF-1R signaling using blocking antibodies or small molecule signaling inhibitors have 
been developed and tested in ovarian cancer. While IGF-1R targeted approaches showed 
promising preclinical activity, they have thus far failed to provide clinical benefit 
(Bruchim and Werner 2013)(Liefers-Visser et al. 2017). 
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  The complexity of IGF-1R signaling in ovarian cancer requires a deeper 
understanding and knowledge of the pathway in the disease. IGF-1R can interact and 
heterodimerize with other receptor tyrosine kinases (RTKs), which may alter ligand 
affinity and activation of downstream signaling (Liefers-Visser et al. 2017). Moreover, 
upon blocking of the IGF-1R pathway, other RTKs may compensate by re-activation of 
pro-survival PI3K/AKT signaling. Increasing evidence in recent years suggests a distinct 
role for ErbB3 signaling in ovarian cancer. An autocrine signal-transducing loop 
involving ErbB3 and its activating ligand HRG has been found to promote cell 
proliferation in human ovarian cancer cells and the effects of HRG/ErbB3 were abrogated 
by genetic or pharmacological ErbB3 inhibition (Sheng et al. 2010). Moreover, tissue 
analysis from ovarian cancer patients indicated an association of ErbB3 or HRG 
expression with decreased patient survival (Tanner et al. 2006)(J. F. Liu et al. 2016). 
Further studies have revealed a high prevalence of ErbB3 and its ligand HRG in ovarian 
cancer (Davies et al. 2014)(Gilmour et al. 2002).  
In this study we characterized the impact of IGF-1R and ErbB3 in ovarian cancer 
growth and therapy resistance and reveal strategies to re-sensitize ovarian cancer cells to 
clinically relevant chemotherapy using istiratumab, a fully human bispecific tetravalent 
IGF-1R- and ErbB3-targeting antibody, composed of a monoclonal IgG1 antibody, 
engineered to contain two single-chain Fv fragments (Camblin et al. 2018)(J. B. 
Fitzgerald et al. 2014). Istiratumab has been previously shown to have two modes of 
action: (i) it blocks IGF-1, IGF2, and HRG binding to their receptors; and (ii) it induces 
degradation of receptor complexes containing IGF-1R and ErbB3 (J. B. Fitzgerald et al. 
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2014).  Our data indicate a potential benefit of dual IGF-1R/ErbB3 inhibition for ovarian 
cancer treatment, and highlight the potential impact of istiratumab in combination with 
standard of care chemotherapy to treat ovarian cancer. 
3.3 Results  
3.3.1 Sensitivity to chemotherapy in ovarian cancer cell lines correlates with cell-surface 
IGF-1R expression, but not ErbB3 expression.  
To investigate the relative importance of cell-surface receptor tyrosine kinase 
expression to chemotherapy sensitivity in ovarian cancer, we determined the proliferation 
response to cisplatin or paclitaxel (Figure 3.1A) across a panel of fifteen ovarian cancer 
cell lines. Cell-surface expression of IGF-1R and ErbB3 was determined by quantitative 
flow cytometry (Figure 3.1B). Area under the curve (AUC) of the chemotherapy dose 
response from Figure 3.1A was plotted against receptor expression from Figure 3.1B, 
and the correlation between chemotherapy resistance and RTK expression was 
determined. These studies identified a statistically significant (p<0.0006 for cisplatin, 
p<0.0014 for paclitaxel) positive correlation between chemotherapy resistance and 
expression levels for IGF-1R, but not for ErbB3 (Figure 3.1C). Investigation of other 
RTKs revealed a positive correlation between AUC and cMET expression, but not EGFR 
or HER2 (Supplementary Figure 3.1A). A multidimensional partial least squares 
regression analysis of all receptor expression correlations with in vitro chemotherapy 
sensitivity revealed IGF-1R expression to be the most heavily weighted contributor 
(Supplementary Figure 3.1B), followed closely by cMET expression. 11 cell lines were 
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also profiled for growth factor mRNA expression (Figure 3.S3), revealing 7/11 may 
express autocrine HRG, whereas only 3/11 may express autocrine IGF-1.  
3.3.2 IGF-1R, ErbB3 and their ligands IGF-1, IGF2 and HRG are highly expressed in 
ovarian cancer patient samples. 
A survey of ovarian cancer patient samples was performed for IGF-1R, ErbB3, 
and their respective ligands. All patient samples tested were positive for IGF-1R protein 
expression (n=11)  with 27% 2+ and 73% 3+. In regard to ErbB3 expression 58% of 
patient samples tested were 2+ positive, and 33% were 3+ (n=12). All samples tested 
were positive for IGF-1 mRNA expression (n=11) with 9% 2+ and 18% 3+. Similarly, 
91% of patient samples were positive for IGF2 mRNA expression with 18% scoring 3+ 
and 55% scoring 4+. 55% of patient samples were positive for HRG mRNA expression 
with a score of 1+ (Figure 3.2A, Table 3.S1). Representative images of staining are 
shown in Figure 3.2B.  
3.3.3 Ovarian cancer cell lines proliferate in response to IGF-1 or HRG stimulation in 
vitro. 
 A panel of ten ovarian cancer cell lines was stimulated with IGF-1 (Figure 3.3A) 
or HRG (Figure 3.3B) and proliferation was assessed via Cell Titer-Glo® Luminescent 
Cell Viability assay after 72 hours. Six out of ten cell lines showed significantly 
increased proliferation in response to IGF-1 treatment, and seven out of ten showed 
significantly increased proliferation in response to HRG stimulation. In all but one cell 
line (PEA2-cis), co-treatment with the bispecific and tetravalent IGF-1R/ErbB3 IgG 
istiratumab resulted in reduction in cancer cell proliferation compared to untreated cells 
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in the presence of IGF-1 (Figure 3.3A), whereas in all but one cell line (PEA1) a 
decrease in proliferation was noted compared to untreated cells in the presence of HRG 
(Figure 3.3B). Of note, dual IGF-1R/ErbB3 inhibition significantly decreased cell 
proliferation in six cell lines even in the absence of recombinant IGF-1 (Figure 3.3A), 
whereas this was the case for four cell lines in the absence of recombinant HRG (Figure 
3.3B). Interestingly, no statistically significant correlation between receptor IGF-1R or 
ErbB3 (r2 = 0.008965, p = 0.7947 and r2 = 0.3197, p = 0.0885 respectively) expression 
levels and sensitivity to istiratumab was observed (Figure 3.S4)  
3.3.4 Dual IGF-1R/ErbB3 inhibition blocks IGF-1 and HRG mediated activation of PI3K 
and MAPK signaling cascades in ovarian cancer cell lines in vitro. 
 Seven serum starved ovarian cancer cell lines were stimulated with IGF-1 or HRG 
for 15 minutes, and then downstream signaling cascades were assessed via western blot. 
AKT and/or ERK phosphorylation was induced in response to IGF-1 and/or HRG in all 
seven cell lines (Figure 4). The addition of the dual IGF-1R/ErbB3 inhibitor istiratumab 
was able to block activation of the PI3K and MAPK signaling cascades (Figure 3.4). 
Looking at the upstream receptor tyrosine kinases involved, istiratumab treatment 
inhibited IGF-1R and/or ErbB3 phosphorylation in response to IGF-1 and HRG 
stimulation. Our data indicate that treatment with istiratumab led to a decrease in total 
IGF-1R and/or ErbB3 protein levels in some cell lines (Figure 3.4). Interestingly cell 
lines showing the greatest inhibition of proliferation in response to istiratumab 
monotherapy in figure 3 (PEO1, OVCAR8, and OV90) also showed the strongest basal 
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p-IGF1R, suggesting a connection between basal activation levels of this receptor with 
drug efficacy .   
3.3.5 Chemotherapy potentiates ligand-mediated activation of pro-survival signaling in 
vitro. 
 To assess how cell lines respond to IGF-1 and HRG while treated with cisplatin, 
paclitaxel, or doxorubicin, OV90, OVCAR8 and PEO4 cells were cultured overnight with 
chemotherapies followed by 15 min IGF-1 (Figure 3.5A) or HRG (Figure 3.5B) 
stimulation. Cells were lysed and AKT phosphorylation was assessed by ELISA. 
Consistent with the Western blot analysis (Figure 3.4), IGF increased AKT 
phosphorylation in OV90, OVCAR8, and PEO4 cells (Figure 3.5A), whereas HRG 
enhanced AKT phosphorylation in OVCAR8 and PEO4 cells (Figure 3.5B). Of note, 
chemotherapy treatment further potentiated a striking increase of pAKT in the presence 
of the growth factors in 9 of 18 chemotherapy-ligand combination conditions, an effect 
that was strongest for paclitaxel (Figure 3.5A,B). In all three cell lines dual inhibition of 
IGF-1R and ErbB3 with istiratumab resulted in pAKT decrease to background levels 
(Figure 3.5A,B).Of note, chemotherapy alone did not increase AKT phosphorylation 
levels with statistical significance (Figure 3.S5).  
3.3.6 Dual IGF-1R/ErbB3 blocking inhibits tumor growth and enhances antitumor 
activity of chemotherapy in vivo. 
 We tested the in vivo effects of dual IGF-1R/ErbB3 inhibition on the antitumor 
activity of three different clinically relevant chemotherapies in mice bearing 
subcutaneous OV90 tumors. The OV90 model was chosen because it grows well in vivo 
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and showed sensitivity to the different chemotherapies. Whereas paclitaxel led to tumor 
control (Figure 3.6A) and liposomal doxorubicin significantly delayed tumor growth 
compared to control (Figure 3.6B), OV90 tumors were resistant to cisplatin in vivo 
(Figure 3.6C). Istiratumab monotherapy led to tumor stasis, whereas the combination of 
dual IGF-1R/ErbB3 inhibition with chemotherapy resulted in tumor regression for all 
three combinations (Figure 3.6). 
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3.4 Discussion 
High recurrence rates following chemotherapy in patients with metastatic ovarian 
cancer emphasize the need for novel treatments. Receptor tyrosine kinases (RTKs) are 
critical effectors of ovarian cancer progression and therapy resistance.  Here we show that 
IGF-1R, ErbB3 and their ligands are expressed in a significant proportion of ovarian 
cancer patient samples. A correlation of increasing IGF-1R expression with decreasing 
sensitivity to cisplatin and paclitaxel was shown across a panel of cell lines representing 
different subtypes of ovarian cancer, including adenocarcinoma (A2780, A2780Cis, 
OVCAR8, OVCAR5, PEO14, PEO23, PEA1, PEA2, SKOV3), serous (OVCAR3, OV90, 
PEO1, PEO4), clear cell (TOV-21G), and endometrioid (TOV-112D) ovarian cancer 
subtypes, suggesting a broad applicability of this research in this disease indication. 
Activating ligands of both IGF-1R and ErbB3 promote ovarian cancer cell proliferation 
and pro-survival signaling activation, whereas dual blocking of IGF-1R and ErbB3 
enhances the efficacy of relevant chemotherapies. 
IGF-1R is a robustly expressed RTK in ovarian cancer, and high expression of 
IGF-1R has been previously shown to correlate with resistance to cisplatin 
chemotherapy(Eckstein et al. 2009). IGF-1R knockdown or signaling inhibition can 
inhibit ovarian cancer cell proliferation(Y. Wang 2005)(Jie Tang et al. 2013) and 
sensitize cancer cells to platinum-based chemotherapy(Beltran et al. 2014). Despite the 
promising preclinical reports, clinical trials did not provide meaningful benefit for 
ovarian cancer patients treated with IGF-1R inhibitors. This was the case when IGF-1R 
inhibitors were used as monotherapy after chemotherapy(Ray-coquard et al. 2013), and 
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when combined with other targeted therapies(Brana et al. 2014). The failure of IGF-1R 
inhibitors in clinical trials is largely attributed to the complexity of RTK pathway 
signaling, including compensatory pathway activation through other RTKs. Monospecific 
targeted therapies may be narrowly focused and parallel signaling pathways may promote 
cancer cell escape from treatment. 
IGF-1R can interact with multiple RTKs that are overexpressed in ovarian cancer, 
such as EGFR, HER2, ErbB3 and c-Met (Liefers-Visser et al. 2017). Our study focused 
on the interaction between IGF-1R and ErbB3 based on increasing evidence for a critical 
role of the ErbB3/HRG signaling axis in this disease. ErbB3 belongs to the ErbB family 
of cell surface receptor proteins, however, in contrast to other ErbB-family members it 
lacks a functioning kinase domain(Jura et al. 2009). Upon binding of the ligand heregulin 
(HRG), ErbB3 heterodimerization with other RTKs is promoted, resulting in potent 
activation of pro-survival PI3K/AKT signaling and resistance against various therapeutic 
modalities, including cytotoxic chemotherapies(Camblin et al. 2018)(Schoeberl et al. 
2017). Screening in ovarian cancer cells using lentivirally-delivered short hairpin RNA 
library targeting RTKs revealed ErbB3 as a relevant target and both genetic and 
pharmacological inhibition of the HRG/ErbB3 axis activation resulted in tumor growth 
inhibition(Sheng et al. 2010)(Mills and Yarden 2010).  
ErbB3 activation involves protein overexpression through increased ERBB3 
transcription and activation through increased autocrine or paracrine HRG signaling, as 
well as ligand-independent activation by other RTKs (Garrett et al. 2011)(Schoeberl et al. 
2017)(Sergina et al. 2007) or through mutations in the extracellular domain of the 
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protein(Arteaga and Engelman 2014). Although multiple RTKs are overexpressed in 
ovarian cancer compared to normal ovarian tissue (Psyrri et al. 2005)(Seiden et al. 
2007)(Kohler et al. 1989)(Campos et al. 2005)(Tanner et al. 2006), no specific addicting 
oncoprotein has been clearly validated in the disease and thus the relative impact of 
different RTKs remains largely unknown. Our analysis of correlation between RTK 
expression and chemotherapy sensitivity in multiple ovarian cancer cell lines suggested a 
correlation for IGF-1R and cMET expression, but not ErbB3. This is consistent with 
previous findings indicating that overexpression of ErbB3 may not be sufficient to 
promote cancer cell proliferation and survival in isolation, but requires activation by 
HRG. Depletion of the activating ligand elicited proliferation arrest in ErbB3 activated 
ovarian cancer cell lines, whereas cell lines with high ErbB3 expression levels but no 
expression of the activating ligand did not show ErbB3 activation and were not sensitive 
to ErbB3 targeting(Sheng et al. 2010). Thus, although our expression analysis in human 
samples suggests strong ErbB3 expression in a significant proportion of ovarian cancers, 
a result that is also supported by previous findings (Campos et al. 2005), ErbB3 
expression alone may not represent a sufficient biomarker for treatment with anti-ErbB3 
molecules. We hypothesize that the ErbB3 ligand heregulin (HRG) may have an 
important role and needs to be critically investigated. Retrospective univariate biomarker 
analysis from a randomized phase 2 trial of the fully-human monoclonal, ligand 
competitive anti-ErbB3 agent seribantumab in combination with paclitaxel in patients 
with advanced platinum-resistant or refractory ovarian cancer suggested that patients with 
detectable levels of HRG had a progression-free survival hazard ratio that favored the 
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experimental arm, whereas undetectable HRG favored the control arm(J. F. Liu et al. 
2016). Further evidence shows that  rearrangements in the gene encoding for HRG, 
NRG1, can drive cancer growth and early clinical data supports the use of ErbB3 
targeting approaches in patients with NRG1-rearranged malignancies(Drilon et al. 
2018).  Together, these findings underscore the necessity to further investigate and 
unravel the impact of HRG in malignancies and critically consider it in the design of 
clinical trials targeting ErbB3. Based on recent evidence showing that the tumor 
microenvironment can cause de novo resistance to PI3K signaling inhibitors by activating 
the HRG/ErbB3 axis(Kodack et al. 2017), it is critical that further scientific efforts 
include investigation of the role of the tumor microenvironment in HRG/ErbB3 mediated 
effects in cancers, including ovarian cancers. 
The close interaction between IGF-1R and ErbB3 signaling has been reported in 
various malignancies. Mechanistic studies showed that CD74-NRG1 fusion gene 
promotes activation of NF-kB signaling pathway in tumors, which in turn enhances the 
secretion of insulin-like growth factor 2 (IGF-2) and phosphorylation of its receptor IGF-
1R(Murayama et al. 2016). Furthermore, recent data suggest that NRG stimulates the 
transcription of IGF2 mRNA in an NF-kB-dependent manner(Tominaga et al. 2017). NF-
kB binding site motifs have been identified in the promoter sequence of IGF-2, leading to 
increased IGF-2 production at the transcriptional level. The IGF-1R/ErbB3 interaction is 
also underscored by data showing that ErbB3 upregulation may compensate for IGF-1R 
receptor blockade in malignancies and vice versa (Camblin et al. 2018)(J. B. Fitzgerald et 
al. 2014)(J. Fitzgerald and Lugovskoy 2011). Moreover, chemotherapies have been 
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shown to increase expression of both IGF-1R and ErbB3 in tumor cell lines, rendering 
these resistant to cytotoxic therapies(Camblin et al. 2018). Together, these data point to 
ErbB3 as potentially critical RTK in the treatment of IGF-1R positive tumors, such as 
ovarian cancer.  
Previous preclinical studies showed very promising potential of istiratumab in 
pancreatic cancer models(Camblin et al. 2018). These data formed the basis for the 
CARRIE study, a double-blind placebo-controlled phase II study of istiratumab in 
combination with nab-paclitaxel plus gemcitabine versus nab-paclitaxel and gemcitabine 
alone in front-line metastatic pancreatic cancer patients with high free IGF-1 serum levels 
(www. clinicaltrials.gov; ID: NCT02399137). Despite the promising preclinical activity, 
istiratumab failed to improve the efficacy of standard-of-care chemotherapy in the front-
line treatment of patients with metastatic pancreatic cancer (A H Ko et al. 2018). The 
reasons for the clinical failure of istiratumab in pancreatic cancer remain unclear and are 
subject to further analysis. This result, however, emphasizes the need for careful and 
detailed clinical exploration of the impact of potential biomarkers in each indication, 
including cancer cell related and tumor microenvironment mediated markers. In this 
respect, the relative role of other RTKs needs to be critically considered. In regard to 
ovarian cancer and ErbB3 for example, the randomized phase 2 trial of the anti- molecule 
seribantumab in combination with paclitaxel in patients with advanced platinum-resistant 
or refractory ovarian cancer showed an increased treatment benefit for patients whose 
tumors had detectable HRG mRNA and low HER2 (J. F. Liu et al. 2016). 
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In summary, our results suggest that the interplay between IGF-1R and ErbB3 
may serve as a regulator of tumor growth and resistance to chemotherapies in ovarian 
cancer. Inhibition of both pathways may sensitize ovarian cancer tumors to 
chemotherapies representing an attractive therapeutic approach in selected patient 
populations.  
3.5 Methods 
3.5.1 Cell lines and reagents 
OV90 cells were obtained from the American Type Culture Collection, OVCAR3, 
OVCAR5, and OVCAR8 cells were obtained from the National Cancer Institute, and 
PEA1, PEA2, PEO1, PEO4, PEO14, and PEO23 cells were obtained from the European 
Collection of Authenticated Cell Cultures. Cell lines were confirmed negative for 
mycoplasma prior to use, maintained according to manufacturer recommendations, and 
propagated for less than 8 weeks after initial plating. IGF-1 and HRG were obtained from 
R&D Systems. Istiratumab was produced by Merrimack Pharmaceuticals, paclitaxel was 
purchased from LC labs, pegylated liposomal doxorubicin was purchased from 
SunPharma, and cisplatin was purchased from Sigma.  
3.5.2 Multi-cellular tumor spheroid growth assays 
Cells were seeded into gel- free scaffold-type microsquare 96-well nano-culture plates 
(SCIVAX) in 4% FBS, grown for 24 hours to allow for the formation of three-
dimensional cell spheroids, then treated as indicated in the figure legends. Cell 
proliferation was assessed via Cell Titer-Glo® Luminescent Cell Viability Assay kit 
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(Promega) as per the manufacturer’s instruction and luminescence was measured on a 
Synergy™ H1 plate reader.  
3.5.3 Quantitative Flow Cytometry 
Cell surface receptor levels were quantified by flow cytometry as previously described 
(Schoeberl et al. 2009). Quantum Simply Cellular IgG bead standards (Bangs 
Laboratories) along with Alexa 647- or allophycocyanin (APC)-conjugated antibodies to 
quantify the number of surface receptors per cell. Beads and cells were analyzed using a 
FACSCanto™ system (BD Biosciences). Data were analyzed using FlowJo software 
(version 8.2). 
3.5.4 In vitro signaling experiments 
For ELISA, cells were seeded into 96-well tissue culture plates (Costar) at 30,000 
cells/well in media supplemented with 4% FBS. The following day, cells were 
synchronized by 24-hour serum starvation in media with 0% FBS. For western blot, cells 
were seeded into 10cm dishes in 10% FBS media and allowed to grow for 24 hours 
before replacing the media with 0.5% FBS media.  Signaling experiments were stopped 
with a cold PBS wash, and cell lysates were generated with Mammalian Protein 
Extraction Reagent (Thermo Scientific) supplemented with phosphatase and protease 
inhibitor pellets (Roche) and 150 mM sodium chloride (Sigma).  
3.5.5 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were performed as previously described (Camblin et al. 2018). Briefly, high-
binding assay plates (Corning) were coated with capture antibodies and incubated 
overnight followed by blocking with 2% bovine serum albumin (BSA, Sigma) in PBS for 
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1 hour. Plates were incubated with lysate diluted two-fold in 2% BSA, 0.1% Tween-20 
PBS for 2 hours, then with primary detection antibodies for 2 hours, followed by 
secondary detection antibodies for 30 minutes. Chemiluminescent substrate (Pierce) was 
added to each plate for 20 minutes and luminescence measured using a Synergy™ H1 
plate reader. Plates were washed 4 times with a PBS solution containing 0.05% Tween-
20 between each incubation, and all incubations were done at room temperature. 
3.5.6 Western Blot Analysis 
Samples were analyzed by western blotting as previously described (Camblin et al. 
2018). Briefly, clarified cell lysates were boiled in LDS sample buffer (Life 
Technologies) at 95°C for five minutes, and resolved by electrophoresis on 4-12% gels 
(Bio-Rad) using MES running buffer (Bio-Rad). Proteins were transferred to 
nitrocellulose membranes (Life Technologies) using an iBlot® device (Life 
Technologies) and membranes were blocked in blocking buffer (LI-COR Biosciences) 
for 1 hour at room temperature. Membranes were probed with primary antibodies (Cell 
Signaling Technology) in 5% BSA (Sigma), 0.1% Tween-20 tris-buffered saline solution 
(TBS-T) overnight at 4-8 degrees Celsius, washed 3 times for 10 minutes in TBS-T, 
followed by incubation with an anti-rabbit secondary antibody (Licor) in 5% milk (Cell 
Signaling Technologies) TBS-T for 45 minutes. After 3 additional 5-minute washes in 
TBS-T, bands were visualized on a LI-COR ODYSSEY® CLx imager. Protein bands 
were quantified using Image Studio (version 3.1.4) software.  
76 
 
3.5.7 Cell Line Derived Xenograft Efficacy Studies 
All animal studies were performed according to the guidelines and with approval of the 
Institutional Animal Care and Use Committee at Merrimack Pharmaceuticals. Female 
athymic nude mice were obtained from Charles River Laboratories and were housed in a 
pathogen-free environment under controlled conditions and received food and water ad 
libitum. Tumors were established by subcutaneous injection of 5x106 cells, suspended in 
200 μL of 1:1 growth factor reduced Matrigel™ (Corning): unsupplemented culture 
media, into one shaven flank of recipient mice. Once the average measured tumor volume 
(calculated according to the formula: π/6 x (length x width x width)) had reached ~230 
mm3, mice were randomized into groups and treatment was administered as outlined in 
figure legends. The average starting tumor volume per group was equivalent across all 
groups. Tumor volumes were measured twice weekly. 
3.5.8 Histology of Tumor Tissue 
Ovarian tumor samples were commercially sourced from Avaden Biosciences, and 
assayed as previously described (J. B. Fitzgerald et al. 2014). Briefly, tumor tissue 
samples were formalin fixed, paraffin-embedded, sectioned to 4-5 μm thickness, and 
analyzed using the Leica Bond Rx or Ventana Benchmark Discovery Platforms. 
Antibodies used for immunohistochemistry (IHC) were as follows: anti-IGF-1R 
(Ventana, G11), anti-ErbB3 (Cell Signaling Technology, D22C5). All IHC-stained 
specimens were scored by a board certified surgical clinical pathologist utilizing the 
clinical HER2 scoring system that classifies each sample into scores 0-3. Detection of 
IGF-1 (#313037), IGF-2 (#594367) and HRG (#311187) transcripts was performed using 
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the in situ hybridization RNAscope® automated assay for the Leica Bond Rx (#321100) 
in accordance with protocols provided by Advanced Cell Diagnostics. For each tissue 
specimen, positive (PPIB, #313907) and negative (DapB, #312037) control RNA probes 
were evaluated to assess tissue quality and assay performance alongside scoring of each 
individual target probe, and scoring was in accoracnece with a 5 tiered scoring system 
(score 0-4) based on counting dots per cell. RNA quantity was scored based on manual 
counting described as follows. Staining results were categorized into five grades 
according to the number of dots visualized under a bright-field microscope. 0: No 
staining or less than 1 dot to every 10 cells (40X magnification); 1+: 1-3 dots/cell (visible 
at 20-40X magnification); 2+: 4-10 dots/cell, very few dot clusters (visible at 20-40X 
magnification); 3+: >10 dots/cell, and less than 10% positive cells have dot clusters 
(visible at 20X magnification); and 4+: >10 dots/cell, and more than 10% positive cells 
have dot clusters (visible at 20X magnification).  
3.5.9 Statistical analysis 
Statistical significance, area under the curved calculations, and curve fitting analysis was 
performed using GraphPad Prism 7 software (version 7.03) as indicated in the figure 
legends.  
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Figure 3.1: IGF-1R expression correlated with reduced sensitivity to chemotherapy 
in ovarian cancer cell lines.  
  
A 
B 
C 
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A, Fifteen ovarian cancer cell lines were treated in triplicate with paclitaxel or cisplatin as 
indicated for 72 hours, and raw luminescent values were normalized to vehicle control 
cells. B, Cell surface expression of IGF-1R and ErbB3 were assessed via quantitative flow 
cytometry across the ten ovarian cancer cell lines. C, Cell line responsiveness to paclitaxel 
or cisplatin from A correlated to cell surface receptor expression from B.  
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Figure 3.2: IGF-1R, ErbB3, and their associated ligands are expressed in ovarian 
tumor patient samples.  
 
A, Percent prevalence for IGF-1R, ErbB3, IGF-1, IGF-2, and HRG in ovarian tumor 
samples as defined as a score between 0 and 3+ for IHC (IGF-1R and ErbB3) or between 
0 and 4+ (IGF-1, IGF-2, HRG). B, Representative images from A showing positive 
staining. Note the diffuse brown staining for IGF-1R and ErbB3 protein staining and the 
punctate brown dots for IGF-1, IGF-2, and HRG RNA in situ hybridization.  
 
  
 
A 
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Figure 3.3: Istiratumab inhibits ligand driven proliferation of ovarian cancer cell 
lines.  
 
Ovarian cancer cells grown overnight in 4% FBS were treated with 50nM IGF-1 (A,) 10nM 
HRG (B,) with and without 1uM istiratumab in duplicate as indicated for 72 hours and 
proliferation was assessed via Cell Titer-Glo® Luminescent Cell Viability Assay. 
Significance was determined by two-way ANOVA using GraphPad Prism software (* 
p<0.033, ** p<0.002, *** p<0.001).  
 
A 
B 
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Figure 3.4: Istiratmab inhibits basal and ligand-induced IGF-1R and ErbB3 
signaling in ovarian cancer cell lines.  
 
Cells were treated with 1uM istiratumab for 60 min followed by 50nM IGF-1 and / or 
10nM HRG for 15 min, then lysed and assayed via western blot for PI3K and MAPK 
signaling activation. Following electrophoresis and transfer of protein samples to 
nitrocellulose membranes, membranes were cut horizontally into thin slices at the predicted 
molecular weights of each target protein to allow for blotting of multiple target proteins 
from a single gel, thus increasing the number of proteins which can be assessed from a 
single sample without stripping the membrane. Each slice was incubated with the 
appropriate primary antibody followed by fluorescently labeled secondary antibodies, 
before being imaged as described in the methods section. Each box presented within the 
figure shows the entirety of a membrane slice, with each separate slice being delineated by 
white space surrounding the image. For ease of interpretation, a black vertical line behind 
the slices delineates when different cell lines were loaded on the same gel, and different 
treatments are indicated with a “+” symbol.  
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Figure 3.5: Istiratumab inhibits AKT activation potentiated by chemotherapy and 
ligand co-treatment.  
 
Cells were treated in triplicate as indicated with IGF-1 (A) or HRG (B) alone or in 
combination with istiratumab, cisplatin, paclitaxel, or doxorubicin for 24 hours, then lysed 
and analyzed for AKT Ser473 phosphorylation by ELISA.  
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Figure 3.6: Istiratumab combines with chemotherapy to regress tumor volume in in 
vivo model of ovarian cancer.  
 
Mice baring OV90 tumors were segregated in to groups of equal average volume (n=10) 
and treated with saline vehicle, 30 mg/kg istiratumab intraperitonially every three days, 20 
mg/kg paclitaxel intraperitonially every 7 days (A,) 5 mg/kg cisplatin intraperitonially 
every 7 days (B,) 3 mg/kg pegylated liposomal doxorubicin intravenously every 3 days 
(C,) or the combination. Tumor volumes were measured twice weekly. The same control 
mice and isitratumab treated mice are represented in each of the subfigures for clarity.  
 
  
 
 A B 
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Figure 3.S1: IGF-1R expression correlated with reduced sensitivity to chemotherapy 
in ovarian cancer cell lines.  
 
A, Cell surface expression of EGFR, HER2, and cMET were assessed via quantitative flow 
cytometry across the fifteen ovarian cancer cell lines. B, Cell line responsiveness to 
paclitaxel or cisplatin from Figure 1A correlated to cell surface receptor expression from 
Figure S1A. C, Weighted results from PLSR analysis correlating receptor expression with 
chemotherapy sensitivity.  
 
  
  
A 
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Figure 3.S2: Induction of AKT phosphorylation in response to growth factor 
stimulation across ovarian cancer cell line panel.  
 
Cell lines were serum-starved for 24 hours and then treated for 15 minutes with 100 ng/mL 
of each growth factor. Cell lysates were collected, and pAKT S473 was determined by 
ELISA. Levels for ng/mL pAKT were control-subtracted and maximum-normalized within 
each cell line. 
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Figure 3.S3: Basal expression of growth factor mRNA across panel of ovarian cancer 
cell lines. 
 
Cell lines were grown in compete media before being lysed for mRNA isolation using the 
RNeasy kit from Qiagen. mRNA expression levels for 8 different growth factors was 
assessed by RTRTPCR, followed by normalization to housekeeping genes using the delta-
deltaCt method. mRNA expression was maximum normalized within each growth factor.  
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Figure 3.S4: Receptor expression levels do not correlate with sensitivity to 
istiratumab monotherapy.  
 
qFACS cell surface receptor expression levels from figure 1 are plotted against istiratumab 
sensitivity from figure 3. No statistically significant correlation is observed.  
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Figure 3.S5: Effects of chemotherapy alone on AKT phosphorylation.  
 
OVCAR8 cells were treated as described in figure 5. No statically significant changes were 
observed in AKT phosphorylation following monotherapy chemotherapy treatment under 
these conditions. 
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CHAPTER 4: TUMOR NECROSIS FACTOR ALPHA SUSTAINS HUMAN 
UMBILICAL VEIN ENDOTHELIAL CELLS ANGIOGENESIS THROUGH TNFR1 
4.1 Introduction 
 
Blood vessel formation is vital not only during embryonic development to ensure 
adequate oxygenation and nutrient supply to growing tissues, but also impacts adult 
organisms by playing a role in processes such as wound repair. As such, dysregulation of 
this process can lead to several disease states, such as tumorigenesis or infarcted 
myocardia. Although cancer incidence has been steadily decreasing in recent years in part 
due to decreased rate of smoking and decreased use of nitrate preservatives in food (R. L. 
Siegel, Miller, and Jemal 2019), this disease remains a leading cause of death in the 
United States (Center for Health Statistics 2017). Much research remains to be done to 
allow for the development of therapeutic agents which can improve the lives of patients 
and improve patient outcomes.  
Angiogenesis is a hallmark of this debilitating disease (Hanahan and Weinberg 
2011). It has been well established that the expression patterns of growth factors such as 
vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF) can 
control the timing and localization of angiogenic events. Inhibiting these factors for the 
treatment of various cancer indications has been clinically validated with approval of 
drugs such as bevacizumab, which has been proven in phase III clinical trials to prolong 
progression free survival in patients (Chinot et al. 2016). Although these clinical 
progression free survival data led to the approval of the anti-angiogenic therapeutic 
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bevacizumab, the treatment interestingly did not improve patient overall survival (Chinot 
et al. 2016). As such, a deeper understanding of the intricacies of the angiogenesis 
hallmark of cancer is required to further extend patient survival. 
Tumor necrosis factor alpha (TNF) is an inflammatory cytokine reported to have 
numerous, pleiotropic effects within the tumor microenvironment (van Horssen, Ten 
Hagen, and Eggermont 2006). This cytokine has been reported to induce cancer cell 
death (Sugarman et al. 1985), cancer cell proliferation (Sugarman et al. 1985), immune 
system activation (Y. L. Wang et al. 1989), immune system inhibition (Chen et al. 2007), 
inflammation (Pikarsky et al. 2004), differentiation (B. Zhou et al. 2015), and endothelial 
expansion and angiogenesis (B. Zhou et al. 2015). However, the precise role of TNF in 
angiogenesis remains controversial. Conflicting studies have reported that TNF can 
inhibit (Schweigerer, Malerstein, and Gospodarowicz 1987)(Fujita et al. 2007)(P. Zhou et 
al. 2017)(P. Zhou et al. 2017) or promote (Zhu et al. 2007)(Pan et al. 2002)(T.-K. Kim et 
al. 2017) angiogenesis. Others suggest TNF’s role in angiogenesis is context dependent 
(Fajardo et al. 1992)(Frater-Schroder et al. 1987). Given that TNFR2 is being proposed as 
a therapeutic target for the treatment of cancer (Tam et al. 2019) and that it has been 
reported that TNF can inhibit angiogenesis (P. Zhou et al. 2017), it is vital to determine 
whether an anti-TNFR2 therapeutic could detrimentally promote angiogenesis within the 
tumor microenvironment.  
TNF binds to one of two receptor homo-trimers, TNF receptors 1 or 2 (TNFR1 
and TNFR2 respectively). It is not yet clear which of TNF’s two receptors mediate its 
92 
 
reported effects on angiogenesis. Several reported in vitro models point towards TNFR1 
as being the driver of angiogenesis (Mackay et al. 1993)(Leeuwenberg et al. 1995), 
whereas several in vivo tumor models have implicated TNFR2 (Sasi et al. 2012)(Ji et al. 
2014). To better understand TNF’s role in angiogenesis and to elucidate the impact of 
anti-TNFR2 treatment on its effects, we used a well-established in vitro model of 
angiogenesis (Maheshwari et al. 1991) with the Angiogenesis Analyzer software for 
ImageJ (Carpentier G, Martinelli M 2012). This assay measures the ability of primary 
human umbilical vein endothelial cells (HUVECs) to form capillary-like tubes on a 
gelled basement membrane. Once plated onto a collagen and laminin containing surface, 
these cells activate membrane bound proteinases to cleave and migrate through the 
extracellular matrix carving tracks towards one another (Davis and Senger 2005). 
HUVEC cells continue to proliferate throughout this process (Tan et al. 2016), and the 
mechanical force necessary to initiate this endothelial cell migration has been reported to 
be dependent on integrin binding to collagen and laminin (Davis and Senger 2005). 
Furthermore, TNF treatment of HUVECs has been shown to upregulate the integrin 
proteins involved in intercellular adhesion (Sheu et al. 1997), as well as cell adhesion 
molecules required for immune cell extravasation (Nakao et al. 2003)(McLaughlin et al. 
1998). 
This work seeks to elucidate the contribution of each of the two TNF receptors to 
the angiogenic process using longitudinal, time-resolved imaging techniques. HUVEC 
angiogenic tube formation was monitored in the presence of ligand-competitive 
antibodies against TNFR1 and/or TNFR2 in order to investigate the specific contribution 
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of each TNF receptor to angiogenesis.  After adapting a reported protocol for HUVEC 
endothelial tube formation (P. Zhou et al. 2017) for longitudinal imaging of this assay, 
we find that TNF supports HUVEC tube maintenance but not HUVEC tube formation, 
and that this TNF mediated tube maintenance is driven exclusively through TNFR1 not 
TNFR2. We hypothesize that these changes in tube maintenance are due to TNF-induced 
increases in cell adhesion molecule expression. 
4.2 Materials and Methods 
4.2.1 Acquisition and maintenance of primary cells 
Human umbilical vein endothelial cells (HUVEC) were obtained from the American 
Type Culture Collection (ATCC PCS-100-013) and maintained in 5% serum (Gibco), 50 
ng/mL bFGF (Peprotech), 50 ng/mL VEGF (Peprotech), and 1% penicillin/streptomycin 
(Gibco) Opti-MEM (ThermoFisher). The inclusion of proangiogenic bFGF and VEGF 
are required for HUVEC proliferation. Cell were passaged in 10 cm dishes for no more 
than six passages following initial thaw.  
4.2.2 Establishment of HUVEC tube formation assay for IncuCyte live-cell imaging 
system 
Clear, flat-bottomed 96-well plates (Corning) were coated with 50 uL of fresh Matrigel 
(Corning) and incubated at 37 C for 20 min to allow for matrix solidification. Cells were 
seeded at 15,000 cells / 50 uL / well, and treatments were added at a volume of 100 uL 
per well, for a total volume within each well of 200 uL (including Matrigel). Cells were 
grown in an IncuCyte live cell imager at 37 C and 5% CO2 for indicated amount of time 
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in each figure. Concentrations of cytokine used (50 ng/mL TNF) and initial treatment 
time (24 hours) replicate the conditions from Zhou et al(P. Zhou et al. 2017), conditions 
which have been shown as a sufficient concentration and sufficient amount of time to 
activate NFkB signaling in HUVECs. Images of endothelial tubes were characterized 
using the Angiogenic Analyzer for ImageJ as described(Carpentier G, Martinelli M 
2012). Default setting were used, and all lengths are in the “pixel” unit. Characterization 
of endothelial tubes is described in the results section for figure 3. Data were plotted and 
statistical significance calculated using GraphPad Prism software.  
4.2.3 Sourcing of anti-TNFR1 and anti-TNFR2 antibodies.  
All antibodies used in this manuscript were commercially obtained. The anti-TNFR1 
(MA5-23706, mouse IgG1 monoclonal from ThermoFisher) and TNFR2 (M1, rat IgG2b 
from BD Bioscience) described as neutralizing of TNF binding to each receptor in their 
respective product sheets.  
4.3 Results 
4.3.1 Establishment of HUVEC tube formation assay for longitudinal imaging in the 
IncuCyte live cell imager. 
Prior to assessing the effects of different treatments on HUVEC tube formation, we first 
optimized conditions to allow for a dynamic range in the assay when cells are stimulated 
with TNF. Replicating the conditions from Zhou et al (P. Zhou et al. 2017), HUVECs 
were seeded onto a Matrigel support with and without 50 ng/mL TNF, and images were 
collected every 12 hours for 24 hours (Figure 4.1A). This assay was performed on either 
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on cells starved overnight of 5% serum but maintained in 50 ng/mL bFGF + 50 ng/mL 
VEGF, or on cells starved overnight of 50 ng/mL bFGF + 50 ng/mL VEGF but 
maintained in 5% serum. Endothelial tubes were observed in serum starved cells 
maintained in 50 ng/mL bFGF + 50 ng/mL VEGF at both 12- and 24-hours following 
seeding onto Matrigel regardless of TNF treatment. In cells maintained in 5% serum 
without additional proangiogenic factors endothelial tubes were observed in all treatment 
conditions at 12 hours following seeding onto Matrigel, however differences were 
observed between vehicle and TNF treatment at 24 hours post seeding. These data lead us 
to choose 24 hours post seeding in bFGF and VEGF starvation conditions moving 
forward (Figure 4.1B).   The bFGF and VEGF conditions will be included in subsequent 
figures as a positive control of angiogenesis.  
4.3.2 Effects of inhibitory anti-TNFR1 and anti-TNFR2 antibodies on endothelial tube 
formation 
Cells were seeded onto the Matrigel support and immediately treated with: 1) un-
supplemented OPTIMEM (vehicle control), 2) 50 ng/mL bFGF + 50 ng/mL VEGF 
(positive control), 3) 50 ng/mL TNF alone, 4) 50 ng/mL TNF + 100 nM anti-TNFR1, 5) 
50 ng/mL TNF + 100 nM anti-TNFR2 or 6) 50 ng/mL TNF + anti-TNFR1, anti-TNFR2 
combination (100 nM each).  Real-time images of tube formation were captured in the 
IncuCyte live cell imager from which time course videos were generated (Figure 4.2). In 
viewing the videos after 24 hours of treatment, the bFGF+VEGF and TNF-treated groups 
appear to show a greater degree of tube formation as compared to vehicle control. The 
addition of anti-TNFR1 to TNF-treated HUVEC yielded a similar degree of tube 
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formation as the vehicle control, whereas addition of anti-TNFR2 to TNF-treated 
HUVEC did not appear to yield an observable difference from TNF alone.  
4.3.3 Quantification of HUVEC tube formation using Angiogenesis Analyzer for ImageJ. 
In order to determine quantifiable differences in HUVEC tube formation between all 
treatment groups, images of each condition at 24 hours after treatment were subjected to 
analysis in the publicly available angiogenesis analyzer for ImageJ as previously reported 
(Carpentier G, Martinelli M 2012). This software analyzes phase contract images of from 
an endothelial tube assay for organization of tubes into branching “skeletons” or “trees”. 
Having identified the overall structures and connections of the tubes, the software goes 
on to quantify characteristics of the tree, including individual numbers of branches, 
extremities (end of branches), nodes (connection between branches), junctions (area 
densely populated by nodes), segments (section of branches between nodes), meshes 
(area surrounded by segments),  and isolated elements (tubes outside of the “tree”), as 
well as population summaries of each of these characteristics such the sum of the length 
of segments and the sum of mesh area. The overlay of each of these parameter 
measurements onto representative images at 24 hours following treatment are found in 
figure 4.3 and are identified by color as described in the figure legend.   
4.3.4 TNFR1 mediates TNF induced effects on HUVEC tube formation 
All angiogenic features quantified from the Image J software output show the same trend 
towards increased angiogenesis following TNF treatment (Figure 4.4), with the 
proangiogenic properties (number of nodes, number of junctions, number of segments, 
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and number of meshes) increasing and the antiangiogenic properties (number of 
extremities and number of isolated segments) decreasing.  Given this consistency 
between endothelial tube characteristics we therefore chose one relevant feature (the sum 
of the length of segments or “total tube length”) to show in the subsequent figures for the 
sake of clarity. Statistical significance between different treatments for the “total tube 
length” characteristic was determined by using a “Tukey's honest significance” one-way 
analysis of variance (ANOVA) test to perform the multiple comparisons being made. 
This method creates a studentized mean range between all treatment groups which 
enables comparison between each treatment group with each other treatment group. 
Relative to vehicle treated HUVECs, TNF treated cells show significantly greater total 
tube length (p<001). There was no significant difference observed between the TNF 
treatment and the bFGF and VEGF positive control treatments (p=0.761). Relative to 
TNF treated cells, anti-TNFR1 treatment and the combination of anti-TNFR1 and anti-
TNFR2 showed significant inhibition (both p<0.001). In contrast, relative to TNF 
treatment, anti-TNFR2 treatment was not significantly different (p=0.993), and relative to 
TNF + anti-TNFR1 treatment, the addition of anti-TNFR2 showed no significant 
difference (p=0.157). Taken together, these data suggest that TNF is a positive mediator 
of angiogenesis in the HUVEC tube formation model, and this process is driven through 
TNFR1 not through TNFR2. 
4.3.5 TNF mediates HUVEC tube maintenance, not HUVEC tube formation 
In viewing the optimization images from figure 4.1, it was unexpectedly observed that all 
treatment conditions form tubes at 12 hours post seeding. After 24 hours of treatment, 
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however, the differences quantified in figure 4.4 are observed. To examine the continued 
maintenance of HUVEC tube structure, images were collected every 12 hours for a total 
of 48 hours, and the previously described “total tube length” was measured for all 
treatment groups (Figure 4.5). Prior to 12 hours, tubes had not yet formed under any 
treatment condition and were therefore not quantifiable. Strikingly, every single treatment 
condition (including vehicle) showed the same degree of initial tube formation at 12 
hours post seeding. Following this timepoint, however, the TNF and bFGF + VEGF 
positive control conditions maintained their tube length. In contrast, vehicle treated 
HUVEC cells lose tube length over time.  Tube length loss was also observed in groups 
treated with TNF + anti-TNFR1 and TNF + anti-TNFR1 + anti-TNFR2, while TNF + 
anti-TNFR2 maintained total tube length over time (Figure 4.5), again supporting that 
TNF mediated HUVEC tube formation is mediated through TNFR1. These data suggest 
that contrary to what is suggested by the name of HUVEC tube formation assays, TNF or 
bFGF and VEGF treatment does not alter tube formation, it alters overall tube 
maintenance.  
4.3.6 Dose dependent inhibition of TNF induced tube maintenance with anti-TNFR1 
titration reveals specificity of results.  
In order to ensure specificity of response in the anti-TNFR1 induced inhibition of TNF 
mediated tube maintenance phenotype, a dose titration of antibody was performed 
(Figure 4.6). The results from figure 4.5 were replicated at 48 hours following treatment 
with the inclusion of the antibody titration. Greater inhibition of total tube length was 
observed with increasing concentrations of anti-TNFR1. In contrast, at no dose was the 
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anti-TNFR2 able to inhibit TNF mediated tube formation. These data support the 
hypothesis that TNF mediated tube formation is driven through TNFR1 binding.  
4.4 Discussion  
TNF treatment  does not appear to increase the rate of tube formation on its own 
as previously reported (Mackay et al. 1993), but rather affects tube maintenance over 
time (Figures 4.1, 2, & 5). The commonly used HUVEC based model of angiogenesis 
may have been misnamed. This observation, made possible by improving on the 
traditional HUVEC tube formation assay with the addition of longitudinal live cell 
imaging, may implicate the need to refine the conclusions of articles previously published 
using this model of angiogenesis. Additionally, the use of the publicly available 
Angiogenesis Analyzer made establishment of statistically significant differences 
possible (Figure 4.3, 4). Longitudinal data collection paired with automated 
computational analysis should be performed for all future studies using this HUVEC 
based angiogenesis assay.  
It has been reported that upregulation of cell adhesion molecules VCAM-1 and 
ICAM-1 occurs on endothelial cells following TNF stimulation (T.-K. Kim et al. 
2017)(Boyce et al. 2002)(Nakao et al. 2003). Additionally, groups have reported that 
integrins avb3 (Sheu et al. 1997) (Maeshima, Colorado, and Kalluri 2000) and a4b7 
(Boyce et al. 2002) are also upregulated in HUVEC cells in response to TNF treatment. 
These groups have shown that this upregulation in cell adhesion molecules improve 
lymphocyte adhesion to a HUVEC monolayer, and postulate this is a method by which 
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TNF can regulate immune cell extravasation into inflamed tissues. To build on this work 
demonstrating TNF treatment increases expression of endothelial cell adhesion 
molecules, we hypothesize an increase in cell adhesion molecules may also be 
responsible for TNF induced increase in HUVEC tube maintenance. Given that the 
HUVEC angiogenesis assay is dependent on a Matrigel gelled basement membrane 
consisting of approximately 60% laminin, 30% collagen IV, and 8% entactin (“Corning 
Matrigel Matrix Frequently Asked Questions” n.d.), adhesion to this extra-cellular matrix 
is likely responsible for prolonged tube maintenance. This implicates TNF may also be 
altering expression levels of laminin and collagen binding integrins, such as a6b1, a6b4, 
a3b1, and a7b1, or a1b1, a2b1, a10b1, and a11b1 respectively (Goswami 2013).Given 
that it has been reported that TNF induced upregulation in cell adhesion molecules is 
dependent on activation of the canonical NFKB pathway (Gwon et al. 2015)(Collins et al. 
1995)(Swamynathan, Loughner, and Swamynathan 2017), further research into the 
interplay between TNF and integrin expression on endothelial cells is warranted.  
Alternatively, TNF treatment has been shown to alter HUVEC proliferation rate (Tan et 
al. 2016), and changes in proliferation within the endothelial tubes could be responsible 
for the prolonged maintenance of the tubes. The specific dynamics of cell proliferation, 
cell death, and cell senescence within the endothelial tubes in response to TNF treatment 
remain to be elucidated.  
Due to the pleiotropic nature of TNF, further elucidation of the dynamics between 
TNF and the tumor microenvironment is necessary for the development of novel anti-
cancer therapeutics. Because tissue inflammation induced by TNF may alter both 
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lymphocyte extravasation as well as tumor angiogenesis, it will be important to determine 
whether blocking angiogenesis may decrease the rate at which immune cells can infiltrate 
in to the tumor microenvironment and thereby decrease response to immune-oncology 
agents.   
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Figure 4.1: Establishment of longitudinal imaging of HUVEC tube formation.  
 
 
(a) Optimization of growth factor conditions for HUVEC tube formation assay. Prior to 
assay initiation cells were maintained in OPTI-MEM (ThermoFisher) supplemented in 
5% fetal bovine serum (Gibco) supplemented with 50 ng/mL bFGF and 50 ng/mL VEGF 
(Peprotech). 24 hours prior to seeding an experiment, media was changed to OPTI-MEM 
without serum supplement of without bFGF and VEGF supplement. Cells were then 
seeded onto a Matrigel layer in 96-well plates and treated immediately as indicated. Cells 
were grown for indicated length of times in the IncuCyte live cell imager with data being 
collected at 12 and 24 hours post treatment. (b) Final experimental workflow diagram for 
HUVEC tube formation assay.  
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Figure 4.2: Videos of HUVEC tube formation.  
 
 
 
Cells were maintained in OPTI-MEM (ThermoFisher) supplemented in 5% fetal bovine 
serum (Gibco) supplemented with 50 ng/mL bFGF and 50 ng/mL VEGF (Peprotech). 24 
hours prior to seeding an experiment, media was changed to OPTI-MEM without the 
bFGF and VEGF supplement. Cells were then seeded onto a Matrigel layer in 96-well 
plates and treated immediately as indicated in the figures. Cells were longitudinally 
imaged to create videos and were treated as indicated. 
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Figure 4.3: ImageJ quantification of HUVEC tube formation from Figure 1 after 24 
hours treatment.  
 
 
Images from the 24-hour timepoint of the videos in figure 2 are quantified using the 
Angiogenesis Analyzer. As described in the results section, green represents the number 
of branches, magenta the number of segments, orange the number of master segments, 
blue sky the mesh area, red surrounded by blue the nodes surrounded by junctions 
symbol, junctions surrounded by red the master junctions, blue number of isolated 
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elements, cyan the number small isolated elements, and red surrounded by yellow the 
number of extremities. 
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Figure 4.4: Graphical representation of quantification of HUVEC tube formation 
from figure 2. TNF mediated HUVEC tube maintenance is TNFR1 mediated.  
 
 
Each of the twenty angiogenic characteristics assessed by the ImageJ Angiogenesis 
Analyzer are plotted for each treatment condition indicated with a “+” symbol. 
Significance was determined by Tukey’s multiple comparison one-way ANOVA test (* 
p<0.033, ** p<0.002, *** p<0.001).  
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Figure 4.5: Treatments do not alter HUVEC tube formation, but instead prolonged 
tube maintenance.  
 
Experiment from figure 3 was repeated with quantification of images every 12 hours 
from 12 hours treatment to 48 hours treatment.  
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Figure 4.6: dose dependent inhibition of TNF induced tube formation with titration 
of aTNFR1 after 48 hours.  
 
Experiment from figure 4 was repeated at 48-hour timepoint and antibody titration as 
indicated.  
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CHAPTER 5: ELUCIDATING THE CONTRIBUTION OF TUMOR NECROSIS 
FACTOR (TNF) RECEPTOR 2 (TNFR2) TO TNF RESPONSE OF CANCER CELLS 
AND DETERMINING DRIVERS OF IN VIVO RESPONSE TO AN ANTI-TNFR2 
THERAPEUTIC. 
5.1 Introduction  
 Cancer is a disease hallmarked by numerous, combined dysregulations. Robert 
Weinberg proposes that cancer driven by numerous features such as sustained 
proliferative signaling, immune system evasion, inflammation, angiogenesis, cell death 
resistance, and others (Hanahan and Weinberg 2011). Although today cancer remains a 
serious and potentially life-threatening disease, great strides have recently been made 
with the advent of novel therapeutic agents. Immune-modulatory therapeutics, which aim 
to induce a patient’s own body to fight off the malignancy, are increasingly being used to 
treat numerous patient populations with several distinct subtypes of this disease, even 
inducing complete responses in patients with diagnoses previously thought to be 
incurable (Maker et al. 2005).  
 Outside of the approved and effective immuno-modulatory agents such as anti-
Programmed Cell Death Protein 1 (PD1), anti-PD1 Ligand (PDL1), and anti-Cytotoxic T-
Lymphocyte-Associated Protein 4 (CTLA4), a large number of novel immune-
modulatory agents are currently under investigation. As of October 18th 2019 
clinicaltrials.gov lists 3,328 actively recruiting, ongoing clinical trials investigating 
therapeutic agents seeking to activate a patient’s immune system for the treatment of 
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cancer (“Search of: Immune | Recruiting Studies | Cancer - List Results - 
ClinicalTrials.Gov” n.d.), of which 2,250 trials seek to combine a novel agent with 
approved anti-PD1 or anti-PDL1 therapeutics. This totals over 389,900 cancer patients 
currently participating in clinical trials (Jun Tang et al. 2018). Despite this enormous 
enthusiasm for the development of novel immune-modulatory therapeutics by the 
pharmaceutical industry, a high failure rate of clinical trials to meet positive clinical 
endpoints has led the US Federal Drug Administrator to give few novel therapeutics their 
commercialization approval (Schmidt 2019). As such, deepening our understanding of 
basic cancer biology in the context of overcoming immune evasion is required to increase 
the likelihood of positive clinical outcomes.  
 Tumor Necrosis Factor (TNF) is a pleiotropic cytokine capable of influencing 
several of Weinberg’s hallmarks of cancer. This cytokine has the capacity to bind to two 
homotrimeric cell surface receptors TNF receptor 1 and TNF receptor 2 (TNFR1 and 
TNFR2) (Bossen et al. 2006). Soluble TNF has been reported to preferentially bind 
TNFR1 whereas membrane-bound TNF may preferentially bind to TNFR2 (Grell et al. 
1995). The interplay between these two receptors and their response to TNF within the 
tumor microenvironment remains to be fully elucidated as each receptor can be expressed 
on many of the numerous cell types within the tumor microenvironment (Hanahan and 
Weinberg 2011). TNF-driven stimulation of each receptor can lead to different 
downstream signaling cascades. While both receptors possess the capacity to activate 
canonical NFκB and MAP kinase signaling, only TNFR2 activates the non-canonical 
NFκB signaling (Borghi, Verstrepen, and Beyaert 2016), suggesting that stimulation of 
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each receptor within the tumor microenvironment may lead to different phenotypic 
outcomes. It has also been shown using co-immunoprecipitation and intracellular 
truncated TNFR2 experiments that TNFR2 can bind TNF, form a higher order structure 
where TNF is bound to both TNFR1 and TNFR2, then TNFR2 can release TNF and 
allow it to fully engage and activate TNFR1 (Pinckard, Sheehan, and Schreiber 1997), 
dubbed the “ligand passing” hypothesis. Similarly, it has been reported that on mouse 
macrophage cells TNFR2 enhances TNFR1 mediated TNF response while having no 
independent function in the absence of TNFR1 (Riches et al. 1998). Furthermore, there is 
research suggesting that TNFR2 within the tumor microenvironment is expressed on 
immune-suppressive cells such as regulatory T cells (Williams et al. 2016)(Chen et al. 
2007). Controversially, several groups have hypothesized that the role of TNFR2 is to 
bind soluble TNF, form a higher-order heteromeric complex with TNFR1 and pass the 
bound TNF to TNFR1 (Lu, Fang, and Chen 2001)(Pinckard, Sheehan, and Schreiber 
1997). We have recently identified TNFR2 as a target for a novel immune-modulatory 
agent (Tam et al. 2019), and this work seeks to elucidate the role of TNFR2 on cancer 
cells in vitro as well as to determine the drivers of in vivo anti-TNFR2 response.  
 Using a panel of eight different syngeneic mouse models of cancer with a 
functioning immune system we first classify models of response or non-response to anti-
TNFR2 therapy, before going on to show that in vivo responsiveness does not appear to 
correlate with TNFR1 expression, TNFR2 expression, or TNF induced MAP kinase or 
NFκB signaling cascades. We demonstrate that knock-out of TNFR2 does decrease in 
vitro sensitivity to TNF, however does not alter the characteristics of response, 
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suggesting TNFR1 and TNFR2 could be functioning redundantly in these models of 
cancer. Using a combination of mouse models with varying levels of immune 
competency, in vivo depletion of specific immune cells, and TNFR2 knock-out cancer 
cell lines we show that CD8 effector T cells are drivers of anti-TNFR2 in vivo efficacy, 
and that this efficacy is dependent on Fc receptor engagement.  
5.2 Materials and Methods  
5.2.1 Cell lines 
The following cell lines were obtained from the American Type Culture Collection 
(ATCC) and maintained in RPMI 1640 (Gibco, with L-glutamine included) 
supplemented with 10% fetal bovine serum (FBS) (Gibco), penicillin (100 U/ml), and 
streptomycin (100 mg/ml) (Gibco, 100× pen/strep solution): CT26 (H-2d) colorectal 
carcinoma (CRL-2638), EMT6 (H-2d) mammary carcinoma (CRL-2755), WEHI-164 (H-
2d) fibrosarcoma (CRL-1751), A20 (H-2d) B lymphocyte (TIB-208), 4 T1 (CRL-2539) 
mammary carcinoma, and B16-F10 (H-2b) melanoma (CRL-6475). The MC38 (H-2b) 
colon adenocarcinoma cell line was obtained from the National Cancer Institute (NCI) 
and maintained in supplemented RPMI 1640. The LLC1 (H-2b) Lewis lung carcinoma 
(ATCC, CRL-1642) was maintained in Dulbecco’s modified Eagle’s medium (Gibco, 
with L-glutamine included) supplemented with 10% FBS and pen/strep. All cells were 
tested for mycoplasma by the supplier or in-house (MycoAlert Mycoplasma Detection 
Kit, Lonza) and confirmed negative. 
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5.2.2 In vivo study design 
Sample size was determined before the study as per Institutional Animal Care and Use 
Committee (IACUC) guidelines. All tumor cells were injected subcutaneously in 100 to 
200 ml of phosphate-buffered saline (PBS) into the right flank of mice that had typically 
been shaved the previous day. The following cell numbers and mouse strains were used 
for inoculation: 3 × 105 cells/mouse for CT26 (BALB/c), EMT6 (BALB/c), WEHI-164 
(BALB/c), A20 (BALB/c), 4T1 (BALB/c), LLC1 (BALB/c), MC38 (C57BL/6), and 
B16-F10 (C57BL/6). Tumor growth was monitored using electronic calipers, and 
volumes were calculated according to the following formula: π/6 × (length × width2). 
When the tumors reached an average size of 50 to 100 mm3, mice were randomized into 
treatment groups to achieve comparable distribution of starting tumor volumes per 
condition. Antibody (300 mg) was injected intraperitoneally as indicated once weekly for 
the number of weeks indicated in the figure legends in a total volume of 200 ml. Mice 
reached endpoint and were euthanized in antitumor activity studies when tumors reached 
2000 mm3 as defined by IACUC guidelines. CR was defined as tumors below 60 mm3 
and continued to regress until the end of the study. The dose of 300 mg was selected 
based on pilot dose-finding studies in three tumor models (CT26, EMT6, and WEHI-
164). No data were excluded, and no outliers were excluded. Studies were not blinded. 
5.2.3 Mice 
We purchased 6- to 8-week-old female BALB/c (BALB/cAnNCrl) BALB/c nudes 
(CAnN.Cg-Foxn1nu/Crl) and C57B6/J (C57B6NCrl) mice from Charles River 
Laboratories. We purchased 6- to 8-week-old Fcer1g−/− [FcRg; C.129P2(B6)-
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Fcer1gtm1RavN12] and FcgRIIb−/− [C.129S4(B6)-Fcgr2btm1TtK/cAnNTac N12] mice 
on the BALB/c background, as well as wild-type BALB/c controls, from Taconic. All 
mice were housed under specific pathogen–free conditions in cages of up to five animals 
and received special rodent diet (Teklad). Studies were approved by Merrimack’s 
IACUC. IACUC guidelines on the ethical use and care of animals were followed. 
5.2.4 Western blot analysis 
Cells were cultured as indicated in the figure legends, then lysed with MPER (Pierce) 
supplemented for protease and phosphatase inhibitors (Roche). Clarified cell lysates were 
boiled in LDS sample buffer (Life Technologies) at 95°C for 5 minutes, and resolved by 
electrophoresis on 4%–12% gels (Bio-Rad) using MES running buffer (Bio-Rad). 
Proteins were transferred to nitrocellulose membranes (Life Technologies) using an iBlot 
device (Life Technologies) and membranes were blocked in blocking buffer (LI-COR 
Biosciences) for 1 hour at room temperature. Membranes were probed with primary 
antibodies in 5% BSA (Sigma), 0.1% Tween-20 Tris-buffered saline solution (TBS-T) 
overnight at 4–8°C, washed three times for 10 minutes in TBS-T, followed by incubation 
with an anti-rabbit secondary antibody (Licor) in 5% milk (Cell Signaling Technology) 
TBS-T for 45 minutes. After three additional 5-minute washes in TBS-T, bands were 
visualized on a LI-COR ODYSSEY CLx imager. Antibodies were sourced as follows: 
pIKKab (Cell Signaling Technology #2697, 1:1000 dilution), IkBa (AbCam #ab32518, 
1:1000 dilution), NIK (AbCam #ab191541, 1:1000 dilution), pNFkB (Cell Signaling 
Technology #3033, 1:1000 dilution), pERK (Cell Signaling Technology #4370, 1:1000 
dilution), pp38 (Cell Signaling Technology #4511, 1:1000 dilution), pJNK (Cell 
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Signaling Technology #4668, 1:1000 dilution), and BActin (Cell Signaling Technology 
#3700, 1:5000 dilution). 
5.2.5 Flow cytometry analysis 
The cell lines indicated in the figure legends were grown to 60-80% confluency, then 
trypsinized, counted, and seperated into 2 x 106 aliquots in a 96-well plate. Cells were 
then washed in PBS, then incubated for 10 min at room temperature in anti-mouse 
CD16/32 (BioLegend 101320) to block non-specific Fc binding. Cells were then washed 
and incubated in fluorescently labeled anti-TNFR1 or anti-TNFR2 as indicated in the 
figure legends for 25 min at room temperature. Following a final wash, samples were 
assessed on an LSRFortessa (BD Biosciences) for fluorescence. Cell populations were 
assessed, and graphs plotted using FlowJo software.  
5.2.6 In vitro tumor cell viability assay 
Cells were seeded into 96- or 384-well culture plates (Corning), allowed to adhere for 24-
hours, then treated for an additional 24 hours as indicated in the figure legends. Cell 
viability was measured using Cell Titer-Glo Luminescent Cell Viability Assay Kit 
(Promega) according to the manufacturer's instructions. Luminescence was measured 
using a Synergy H1 plate reader. 
5.2.7 Functional antibody sources 
The chimeric mouse Fc, rabbit CDR TNFR2 targeting IgG2a using in the in vivo  efficacy 
studies (Y9) was obtained and characterized as we have previously described(Tam et al. 
2019). The anti-TNFR1 used in in vitro studies (clone 55R170) was obtained from R&D 
116 
 
Systems, and the agonistic anti-TNFR2 (54.7) was obtained from BioXCell. These 
antibodies all bind to the extracellular domains of TNFR1 or TNFR2 in a TNF 
competitive fashion. 
5.3 Results  
5.3.1 Surveying a panel of mouse cancer models for response to anti-TNFR2 treatment. 
Eight syngeneic, immunocompetent mouse models of cancer were evaluated for response 
to the anti-TNFR2 therapeutic mouse IgG2a antibody, designated “Y9” (Figure 5.1). 
These models are from numerous cancer indications and were isolated from different 
mouse backgrounds as indicated in the methods section, and therefore represent a diverse, 
unbiased panel of in vivo models with which to assess anti-TNFR2 efficacy. Mice 
inoculated subcutaneously with each tumor model were randomized into treatment or 
vehicle (PBS) groups when tumor volumes reached ~60 mm3 and treated once with 300 
µg of anti-TNFR2 as indicated with a vertical dotted line. Tumor volume was monitored 
over time, and the Y9 treatment group was compared to vehicle (PBS) treated mice. 
Complete responders were identified as mice with a tumor volume <60 mm3 at the end of 
study. 4 / 8 models were responsive to anti-TNFR2 treatment and classified as “models 
with complete response” (CT26, EMT6, WEHI164, and MC38), 1 / 8 models was 
responsive to anti-TNFR2 treatment but did not develop a complete response by end-of-
study (A20), and 3 / 8 models were classified at “non-responding models” (4T1, B16F10, 
LLC1) in which anti-TNFR2 treatment had no anti-tumor activity. Overall, response to 
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anti-TNFR2 therapy was observed in 5/8 models, thereby validating TNFR2 as a 
potential drug target. 
5.3.2 Relationship between in vivo response, TNFR1 and TNFR2 expression, and TNF 
induced signaling response. 
Cells from the same cell lines used to generate the eight tumor models tested in figure 1 
were cultured in vitro and assessed via flow cytometry for basal, unstimulated TNFR1 
and TNFR2 expression (Figure 5.2A) as described in the methods section. These data are 
plotted as median fluorescent intensity and cell lines rearranged by degree of in vivo 
response in Figure 5.2B. Signaling response to TNF stimulation in each of these cell 
lines was also assessed by western blot as described in the figure legends (Figure 5.2C). 
No apparent relationship between TNFR1 or TNFR2 expression and in vivo response to 
treatment was observed, as the models expressing both the highest TNFR2 (WEHI164 
and CT26) and the lowest TNFR2 (A20 and MC38) were all classified as responding 
models. Similarly, no relationship was observed between TNFR1 expression and 
response. With regards to signaling response (Figure 5.2C), all cell lines exhibit 
canonical NFκB (IKKab phosphorylation, IkBa degradation, NFκB phosphorylation) and 
MAP kinase (ERK, p38, or JNK phosphorylation) expression with the exception of A20 
(which was identified as having a TNFR1 and TNFR2 expression level by flow 
cytometry similar to background, and therefore does not express qualifiable levels of 
either receptor). There are differences in degree and timing of signaling activation 
between cell lines, and only EMT6, LLC1, and MC38 appeared to induce ERK 
phosphorylation following TNF stimulation. Interestingly, no cell line showed non-
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canonical NFκB signaling with NIK degradation which has been reported to occur 
following TNF activation of TNFR2(Borghi, Verstrepen, and Beyaert 2016). Cancer cell 
receptor expression and TNF responsiveness must not be the determining factors for in 
vivo anti-TNFR2 response.  
5.3.3 Use of TNFR2 knock-out cells indicate role for TNFR2 on cancer cell line. 
CRISPR-Cas9 methodology was used to engineer the EMT6 cell line to not express 
TNFR2 as we have previously described(Tam et al. 2019). Signaling response to TNF 
stimulation was compared between the wild-type parental EMT6 cell line (EMT6 WT) 
and the engineered knock-out (EMT6 TNFR2 -/-). A dose titration of TNF at 5 (Figure 
5.3A) or 15 (Figure 5.3B) minutes revealed that the knock-out cell line is less sensitive 
to TNF, with both a lesser NFκB and MAP kinase response as compared to the parental 
cell line. Interestingly despite the reduction in sensitivity to TNF no changes in which 
signaling nodes are activated were observed between the parental and knock-out cells, 
indicating that TNFR2 engagement with TNF does not lead to different signaling 
pathway activation in this model compared to TNFR1 alone. Similarly, in performing a 
dose titration of TNF assessing cell viability response to TNF stimulation via CellTiter 
Glo assay, the TNFR2 knock-out EMT6 cells showed less sensitivity to TNF (Figure 
5.3C). In order to validate these data from the knock-out cell line, the effect of ligand 
competitive anti-TNFR1 and anti-TNFR2 antibodies(Sheehan et al. 1995) on TNF-
induced cell viability in EMT6 cells was assessed. We first determined what 
concentration of antibody is sufficient to fully occupy cell surface TNFR1 or TNFR2 
proteins by titrating each antibody on EMT6 cells, followed by staining of the cells with a 
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fluorescently labeled version of the same antibody (Figure 5.4A). A saturating dose is 
achieved when no TNFR1 or TNFR2 is available for the fluorescently labeled antibody to 
bind. We chose 100 nM of either antibody moving forward. Wild-type or TNFR2 knock-
down EMT6 cells were treated with a TNF titration as in Figure 3C following 
preincubation for 1 hour of 100 nM anti-TNFR1, 100 nM anti-TNFR2, or the 
combination of 100 nM TNFR1 and 100 nM TNFR2 (Figure 5.4B). In the wild-type 
cells (IC50 of 0.1186 nM), both TNFR1 (IC50 of 2.760 nM) and TNFR2 (IC50 of 
1.242nM) blockade inhibited TNF-induced phenotypic changes by one order of 
magnitude in IC50, and their combination additively inhibited response by an additional 
order of magnitube shift in IC50 (IC50 of 23.55 nM). In the TNFR2 knock-out EMT6 
cells, the anti-TNFR2 treatment (IC50 of 4.490 nM) had no effect over vehicle treatment 
(IC50 of 4.161 nM), and the combination of anti-TNFR2 with anti-TNFR1 (IC50 of 
60.95 nM) showed no increased effect over anti-TNFR1 alone (IC50 of 72.89 nM). 
Despite not correlating with in vivo response, cell line TNFR2 expression does influence 
responsiveness to TNF stimulation. 
5.3.4 Clustering TNFR2 on cell surface of cancer cell lines does not activate the receptor 
Since we have shown in figure 4 that cell surface TNFR2 does contribute to cancer cell 
line TNF response, we now sought to determine the different ways in which an anti-
TNFR2 may affect cell viability. The TNFR2-targeting IgG clone 54.7 has been 
reported(Williams et al. 2016) to agonize TNFR2 when clustered with a goat polyclonal 
anti-Fc antibody against, leading to NFκB pathway activation in a TNFR2 
overexpressing, NFkB luciferase reporter HEK293T cell line. It is possible TNFR2 
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agonism may be contributing to in vivo response to anti-TNFR2 therapy, which may have 
direct effects on cell viability either with or without TNF co-stimulation. To assess 
whether the anti-TNFR2 mouse IgG2a antibody Y9 can agonize TNFR2 expressed 
cancer cell lines, clustering was first performed as described(Williams et al. 2016) for 
Y9, as well as with the positive control 54.7 antibody. We then validated the clustering 
technique by size exclusion chromatography (Figure 5.5A). In each case, the clustering 
method resulted in a shift in elution peaks towards an earlier elusion time, indicating that 
Y9 and the anti-Fc combine to form a larger protein complex in solution. We next 
assessed the direct effects on cell growth of the clustered antibody (Figure 5.5B). 
Stimulation of the 4T1, CT26, EMT6, and WEHI164 cell lines with either un-clustered 
antibody, clustered antibody, or clustering goat polyclonal antibody alone for 24 hours 
induced no changes in cell viability by CellTiter Glo assay either for Y9 or for the 
positive control 54.7 clustered antibody.  
We next assessed whether clustering of the TNFR2 antibodies will alter 
phenotypic response to TNF stimulation (Figure 5.5C). Neither 4T1 nor CT26 showed 
any sensitivity to TNF treatment. The EMT6 and WEHI164 models showed growth 
inhibition when treated with TNF. Similarly to the results in figure 4, the ligand 
competitive TNFR2 antibodies were able to partially inhibit TNF induced inhibition in 
tumor growth. The addition of clustering, however, did not alter anti-TNFR2 inhibition of 
TNF induced changes in cell viability. Clustering the TNFR2 targeting antibodies had no 
effect on antibody function on cancer cell lines. These results indicate that cancer cell 
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TNFR2 may not be contributing to in vivo anti-TNFR2 response. Tumor infiltrating 
immune cell may be responsible.  
5.3.5 Anti-TNFR2 treatment inefficacious in immunodeficient nude mice 
In order to assess the contribution of T cells to anti-TNFR2 efficacy, the efficacy of 
TNFR2 inhibition was assessed side-by-side in BALB/c wild-type and BALB/c nude 
mice which lack a thymus mature T cell compartment in three models shown in figure 1 
to respond to anti-TNFR2 treatment (Figure 5.6). The efficacy of anti-TNFR2 treatment 
from figure 1 was reproduced in the A20, CT26, and WEHI164 models in wild-type 
mice, while anti-TNFR2 treatment groups overlapped completely with PBS vehicle in the 
nude mice. T cells therefore appear to be required for in vivo anti-TNFR2 response.  
5.3.6 In vivo immune cell depletion and ex vivo T cell culture suggest anti-TNFR2 
efficacy driven by CD8 cells 
Efficacy of anti-TNFR2 treatment in the CT26 model was assessed in wild-type BALB/c 
mice in which CD8 effector T cells, Natural Killer (NK) cells, or CD4 helper T cells were 
depleted via antibody treatment as we have previously described(Tam et al. 2019). 
Figure 5.7A shows that depletion of CD8 cells completely ablates the efficacy of anti-
TNFR2 treatment, whereas NK cell depletion partially inhibits anti-TNFR2 induced 
efficacy. CD4 depletion resulted in loss of tumor growth even in the untreated group. In 
order to ensure engraftment in a CD4-depleted mouse,  the CT26 tumor model cells were 
grown in Matrigel as previously reported(Kamphorst et al. 2017), and showed that Y9 
remained efficacious following CD4 depletion(Figure 5.7B). Furthermore, an efficacy 
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study in BALB/c wild-type mice using TNFR2 knock-out EMT6 cells (Tam et al. 2019) 
was performed (Figure 5.7C). In the TNFR2 knock-out EMT6 and CT26 models anti-
TNFR2 efficacy was maintained. To test the direct effects of anti-TNFR2 on CD8 cells, 
CD8s were isolated as we previously described(Tam et al. 2019), then cultured ex vivo 
with either soluble or plate bound anti-TNFR2 (Figure 5.7D). In response to plate bound 
Y9, CD8 cells increased in proliferation, increased levels of the T cell activation marker 
CD25 (IL-2 receptor), as well as increased CD8 cell granzyme production. Soluble anti-
TNFR2 did not increase CD8 cell proliferation, activation, or granzyme production. CD8 
T cells are the drivers of anti-TNFR2 in vivo response.  
5.3.7 In vivo efficacy of anti-TNFR2 mediated by Fc receptor engagement 
Given that CD8 T cell depletion completely ablates anti-TNFR2 efficacy response in vivo 
and that CD8 T cells can mediate antibody activity through Fc receptor engagement, we 
sought to determine whether Fc function is required for anti-TNFR2 efficacy. Fc receptor 
engagement allows cells to bind one another, allowing intercellular signaling events. 
Removing effector function from the TNFR2 targeting antibody may prevent CD8 T cells 
from acting on neighboring cells. Efficacy studies in the “models with complete 
response” CT26, EMT6, and WEHI164 were repeated comparing anti-TNFR2 with a 
wild-type mouse IgG2a backbone as in figure 1 to that with mutations abolishing Fc 
receptor engagement for the IgG2a, D265A and N297A (Shields et al. 2001) (dubbed 
“DANA”) (Figure 5.8A). These mutations remove Fc glycosylation sites required for Fc 
receptor engagement (Shields et al. 2001). Anti-TNFR2 efficacy is lost completely when 
antibodies harbor the DANA mutations This suggests that Fc function is required for 
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anti-TNFR2 efficacy. To validate this result using an orthogonal method, efficacy of the 
anti-TNFR2 was assessed in wild-type BALB/c mice, BALB/c knockout mice that lack 
the FcgRIIb receptor (Fcgr2b−/−) which inhibits immune cell activation upon Fc 
engagement, and BALB/c knockout mice that lack the common Fc-gamma chain 
(Fcer1g−/−) required for FcgRI, FcgRIII, and FceRI mediated Fc engagement and 
immune system activation (Figure 5.8B) (Takai et al. 1994)(Bruhns 2012). Similar to the 
use of anti-TNFR2 harboring the DANA mutations, the anti-TNFR2 once again lost 
efficacy. Since knock-out of both the inhibitory and activating Fc receptors lead to loss of 
efficacy, that the contribution of Fc receptor engagement to anti-TNFR2 in vivo efficacy 
may be to induce antibody clustering. Taken together, these data suggest in vivo agonism 
of CD8 T cells is mediated by Fc receptor induced clustering of the anti-TNFR2 
antibody.  
5.4 Discussion  
Our results show that cancer cell TNFR2 expression and responsiveness to TNF 
stimulation do not appear to be predictors of response to in vivo anti-TNFR2 treatment 
(Figures 5.1 & 2). Despite cancer cell TNFR2 expression levels not correlating with in 
vivo efficacy, the use of TNFR2 knock-out cells (Figure 5.3) and ligand competitive 
TNFR2 antibodies (Figure 5.4) revealed that TNFR2 does enhance TNF stimulation 
response in vitro.  This phenomenon could be explained by three main hypotheses: 1) 
TNFR1 and TNFR2 are functioning redundantly in these models, resulting in no 
phenotypic or signaling differences in response to TNF stimulation regardless of which 
receptor becomes bound by ligand. 2) The role of TNFR2 may be to pass TNF through a 
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higher order hetero-complex to TNFR1. 3) TNFR2 is enhancing TNF induced TNFR1 
activation through an alternate mechanism. The first hypothesis, that TNFR1 and TNFR2 
are functioning redundantly, is unlikely. TNFR1 and TNFR2 are known to be structurally 
distinct (F. K. M. Chan, Siegel, and Lenardo 2000) with different intracellular protein 
binding partners, therefore making true redundancy between the two receptors 
improbable. We know from figure 4A that 100 nM of anti-TNFR1 is a sufficient 
concentration to saturate cell surface EMT6 TNFR1 protein molecules. If ligand passing 
were occurring, there should be no additive effects of combining an additional 100 nM 
anti-TNFR2 on top of the 100 nM anti-TNFR1. In figure 4B, however, we do see additive 
inhibition of TNF induced changes in cell viability induced by the combination of 100 
nM anti-TNFR1 with 100 nM anti-TNFR2. Therefore, of the three hypotheses presented 
the data therefore suggests the third is most likely: the TNFR2 is enhancing TNFR1 
function. In order to further prove this hypothesis, a cell line with TNFR1 knocked out 
could be generated. In the event TNFR1 knock-out does not completely abolish TNF 
response, then the role of TNFR2 could not be to pass the ligand.  
Given 1) that anti-TNFR2 treatment had no observable in vitro effect in the 
absence of TNF (figure 5.5), 2) that no in vivo activity was observed in immunodeficient 
mice (Figure 5.6), 3) that anti-TNFR2 treatment group in immunodepleted mice revealed 
CD8 effector T cells are required for anti-TNFR2 activity (Figure 5.7A), and 4) that 
tumors from cancer cells deficient in TNFR2 maintained responsiveness to anti-TNFR2 
activity (Figure 5.7C), it can be concluded that cancer cell TNFR2 expression does not 
impact responsiveness to an anti-TNFR2 therapeutic. It is interesting to observe that CD8 
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depletion (Figure 5.7A) but not CD4 depletion (Figure 5.7B) led to loss of anti-TNFR2 
efficacy, as other groups (Williams et al. 2016)(Torrey et al. 2017) have reported the 
efficacy of antagonistic anti-TNFR2 therapeutics is driven by inhibiting regulatory CD4+ 
T cells (Treg). Within the tumor microenvironment the balance between immune cell 
activation and immune cell inhibition is regulated by the CD8 : Treg ratio (Sato et al. 
2005), with a higher ratio being prognostically favorable. Whether targeting TNFR2 is 
antagonizing regulatory T cells or agonizing CD8 cell, the CD8 : Treg ratio may still be 
favorably increasing.  
Although clustering of the TNFR2 antibody had no effect on the properties of 
cancer cell lines (Figure 5.5), plate bound (clustered) but not soluble (un-clustered) anti-
TNFR2 agonized CD8 T cells (Figure 5.7D). Taken together with the observation that Fc 
receptor engagement is a requirement for in vivo efficacy (Figure 5.8), it is possible that 
the role of anti-TNFR2 binding to Fc receptor is to cluster and activate the receptor to 
agonize CD8 T cells. Although Fc receptor engagement by therapeutic antibodies is 
canonically associated with target cell depletion (as is the case with HER2 
overexpressing cell and the anti-HER2 Herceptin), depletion of CD8 cells would have a 
negative effect on inhibiting tumor growth. Additionally, knock-out of TNFR2 on the 
cancer cell lines did not alter in vivo efficacy suggesting cancer cell depletion is not 
driving in vivo anti-TNFR2 efficacy.  
It remains to be seen which Fc receptor expressing cell population is responsible 
for in vivo anti-TNFR2 clustering and subsequent CD8 cell agonism. The activating 
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FcgRI and FcgRIII are typically expressed on monocytes, macrophages, and dendritic 
cells, and the inhibiting FcgRIIB is typically expressed on B cells and dendritic cells 
(Takai et al. 1994). Given that knock out of either activating or inhibiting Fc receptors 
lead to loss of in vivo anti-TNFR2 efficacy, dendritic cells expressing either receptor 
could be responsible. Alternatively, multiple cell populations could simultaneously be 
contributing to anti-TNFR2 clustering. Interestingly, neoantigens which are highly 
expressed within the tumor microenvironment (Taylor and Odiu 1970)(Zorn and Hercend 
1999) have been shown to be able to induce Fc receptor expression on CD8 T cells 
(Starbeck-Miller et al. 2014), implying it is possible that CD8 T cell Fc receptors are 
binding anti-TNFR2 Fc and inducing clustering-mediated agonism of neighboring CD8 T 
cells. Further research is required to elucidate which cell population(s) is/are responsible 
for CD8 agonism.  
This work solidifies TNFR2 within the category of novel immune-modulatory 
targets called “co-stimulatory” molecules. This class of molecules targets T cell surface 
proteins such as OX40, 41BB, and GITR, which are currently the targets of therapeutic 
agents undergoing clinical investigation in combination with immune checkpoint 
blockade. We have developed humanized surrogate of the anti-TNFR2 used in these 
experiments (Tam et al. 2019), and is currently awaiting clinical development.  
 
  
127 
 
Figure 5.1: Survey of efficacy response to anti-TNFR2 therapeutic across eight in 
vivo syngeneic mouse models.  
 
Mice harboring A20, 4T1, B16F10, CT26, EMT6, LLC1, MC38, or WEHI164 tumors 
were randomized to ensure even tumor volumes across two treatment groups: vehicle 
(PBS, blue) or anti-TNFR2 (Y9, red). Mice were treated once with 300 ug of Y9 as 
indicated with the vertical dotted line on each efficacy plot. Tumor models are grouped 
together by degree of response to anti-TNFR2 therapy. These experiments were repeated 
at least once by independent researchers to reduce the likelihood of bias during the data 
collection process.  
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Figure 5.2: No trend between in vivo anti-TNFR2 response and in vitro receptor 
expression of TNF signaling response.  
 
129 
 
 
A, Cancer cells from the A20, 4T1, B16F10, CT26, EMT6, LLC1, MC38, or WEHI164 
models cultured in vitro were assessed for TNFR2 or TNFR1 expression by flow 
cytometry. Cells were stained with BV421 labeled anti-TNFR2 and with APC labeled 
anti-TNFR1, which can be compared to the background levels of fluorescence for each 
cell line. B, Data from A are replotted as bar graphs representing the median fluorescent 
intensities for TNFR1 or TNFR2 staining from each cell line, and are arranged by degree 
of in vivo response. C, A20, 4T1, B16F10, CT26, EMT6, LLC1, MC38, or WEHI164 
were treated with 200ng/mL TNF for the indicated time period prior to cell lysis and 
western blot analysis for each of the indicated proteins. These experiments were 
performed one time in quadruplicate.  
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Figure 5.3: TNFR2 knock-out decreases in vitro cell line phenotypic and signaling 
response to TNF stimulation.  
 
A,B, To compare TNF induced signaling dose response in WT and TNFSFR1b-/- EMT6 
cells, cells were stimulated with the indicated titration of TNF for 5 min (A) or 15 min 
(B) then subjected to western blotting analysis. At both time points the TNFR2 knock out 
cells show a strong decrease in TNF sensitivity as compared to the wild-type cells. C, 
Decrease in sensitivity to TNF is observed in the TNFR2 knock-out model in cell 
viability assay after 48 hours of growth. These experiments were performed one time in 
quadruplicate.  
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Figure 5.4: In vitro stimulation of TNF induced phenotypic response inhibited by 
anti-TNFR1 / 2 antibodies in EMT6 cells.  
 
A, EMT6 cells were first treated with the indicated concentrations of unlabeled anti-
TNFR1 or anti-TNFR2, then stained with fluorescently labeled anti-TNFR1 or anti-
TNFR2 to determine the degree of unbound TNFR1 or TNFR2 protein. B, EMT6 WT 
and TNFR2 knock-out cells were treated with the saturating concentration of 100 nM 
anti-TNFR1, 100 nM anti-TNFR2, or the combination of 100 nM anti-TNFR1 and 100 
nM anti-TNFR2 for 1 hour, then treated with indicated concentration of TNF. Cell 
viability was assessed after 48 hours of growth. These experiments were performed one 
time in quadruplicate.  
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Figure 5.5: Effects of clustering on antibody function.  
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A, Anti-TNFR2 clustering from Williams et al(Williams et al. 2016) is validated by size 
exclusion chromatography. B, Cell viability of 4T1, CT26, EMT6, and WEHI164 cells 
was assessed after 48 hours of treatment with either clustered of un-clustered anti-TNFR2 
antibodies, 54.7 being the positive control reported from Williams et al and Y9 the anti-
TNFR2 used in our in vivo efficacy studies.  C, Effect of clustered anti-TNFR2 antibodies 
on TNF induced changes in cell viability after 48 hours of treatment. These experiments 
were performed one time in quadruplicate.  
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Figure 5.6: Loss of in vivo efficacy in nude mice of anti-TNFR2 treatment suggests T 
cells required for response.  
 
BALB/c wild type and BALB/c nude T cell deficient Mice harboring the known anti-
TNFR2 responding A20, CT26, or WEHI164 tumors were randomized to ensure even 
tumor volumes across two treatment groups: vehicle (PBS, blue) or anti-TNFR2 (Y9, 
red). These experiments were performed one time with between six and fifteen mice per 
group.  
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Figure 5.7: In vivo immune cell depletion and ex vivo T cell culture suggest anti-
TNFR2 efficacy driven by CD8 cells.  
 
A, In vivo activity of Y9 treatment after depletion of CD8+ T cells, NK cells, CD4+ T 
cells, and no depletion control in the CT26 syngeneic murine tumor model. Once tumors 
were established, mice were given a single injection of 1 mg of Y9 intraperitoneally; 
individual mice are shown. CR, tumors below 60 mm3 and continued to regress until the 
end of the study. Group sizes are indicated in the figure. B, In vivo activity of Y9 
treatment (300 mg × 3 weeks) after depletion of CD4+ T cells and no depletion control in 
CT26 tumor model established with Matrigel matrix. Group sizes are indicated in the 
figure. Vertical dashed lines indicate days of treatment. C, In vivo activity of Y9 in 
TNFR2 CRISPR knockout models CT26-CrKO (n = 5 mice per group) and EMT6-CrKO 
(n = 10 mice per group). Mice were given three weekly treatments of 300 mg of antibody 
intraperitoneally Individual mice are shown. D, Proliferation and activation of purified 
splenic CD8+ T cell co-stimulation comparison with various concentrations of plate 
bound versus soluble Y9 (2ug/mL plate bound anti-CD3 and 1 μg/mL soluble anti-
CD28). Work in this figure was not collected by Adam Camblin.  
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Figure 5.8: In vivo efficacy mediated by Fc receptor engagement.  
 
A, Comparison of in vivo activity of Y9 with wild-type Fc (Y9) and DANA mutant Fc 
(Y9-DANA) shown as survival curves in three syngeneic mouse models. Antibodies were 
injected intraperitoneally at 300 mg on days 5, 12, and 19 after tumor inoculation. 
Statistically significant differences from PBS are indicated (PBS, n = 10; Y9, n = 15; Y9-
DANA, n = 10). B, In vivo activity of Y9 in CT26 syngeneic murine tumor model in 
BALB/c wild-type (WT), Fc receptor common g-chain knockout (Fcer1g−/−), and 
FcgR2b knockout (Fcgr2b−/−) mouse strains. Data are shown as survival curves. 
Antibodies were injected intraperitoneally at 300 mg on days 8, 15, and 22 after 
inoculation. Statistically significant differences from WT is indicated (n = 10 mice per 
group). These experiments were performed one time.  
  
137 
 
CHAPTER 6: DISCUSSION 
Cancer is hallmarked by having multiple drivers and furthering our understanding 
of the interplay between these drivers will enable to more efficient drug design and 
inform better drug combinations in the clinic. In this dissertation we have shown that 
growth factors coopted within the tumor microenvironment by cancer cells to maintain 
their highly proliferative and pro-survival state can be inhibited with a tetravalent, 
bispecific antibody, and that agonizing tumor infiltrating CD8 positive effector T cells 
with a monoclonal antibody against TNFR2 can drive in vivo anti-cancer efficacy.  
6.1 Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and 
Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer 
 In chapter two we showed that IGF-1 and HRG are the two growth factors most 
capable of activating pro-survival PI3K signaling across a panel of pancreatic cancer cell 
lines. The third most potent growth factor, however, was HGF, the ligand partner for the 
MET receptor. This suggests that MET may be a potential target for the treatment of 
pancreatic cancer, and a similar study of MET’s contribution to chemotherapy resistance 
is warranted. Indeed, high MET expression in pancreatic cancer patients has been shown 
to correlate with poor survival rates (J. H. Kim et al. 2017), and other groups have 
investigated the efficacy of a MET inhibitor for treatment of this disease (Jin et al. 2008).   
In this chapter we also showed that the bispecific tetravalent antibody specific for 
IGF-1R and ErbB3 (istiratumab) is able to restore paclitaxel and gemcitabine sensitivity 
lost due to growth factor stimulation. Although these two chemotherapies are widely used 
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to treat pancreatic cancer, three others, irinotecan, oxaliplatin, and fluorouracil (Conroy et 
al. 2011), are also used for the treatment of this disease. Future work investigating 
whether IGF-1 and HRG induce loss of sensitivity to these chemotherapies could expand 
the clinical applicability of this work. The in vivo efficacy experiments in figure 2.6 could 
be repeated assessing the combination of isitratumab with irinotecan, oxaliplatin, or 
fluorouracil.  
A phase II study investigating the efficacy of istiratumab in combination with 
gemcitabine and nab-paclitaxel was performed, and the preclinical activity shown in 
chapter two did not translate into the clinic. In this study there was no statistically 
significant difference in overall survival between gemcitabine and nab-paclitaxel alone vs 
gemcitabine, nab-paclitaxel and istiratumab (A H Ko et al. 2018). This lack of translation 
from bench to bedside calls into question the methods used to preclinically evaluate drug 
targets. In this chapter, all in vivo work was performed in immunodeficient mice and 
therefore may not fully recapitulate a patient’s tumor microenvironment. Further work 
could be done to investigate how this antibody interacts with the immune system when 
combined with gemcitabine and nab-paclitaxel. 
6.2 Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for 
ovarian cancer 
 In chapter three we showed that IGF-1R cell surface expression levels correlate 
with sensitivity to cisplatin and paclitaxel in a panel of ovarian cancer cell lines. 
Although chemotherapy sensitivity did not correlate with the expression of ErbB3 or 
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other ErbB family members on cancer cell lines, RTKs outside of the ErbB and Insulin 
Receptor family were not assessed. It would be beneficial to see whether RTK expression 
alters sensitivities to other chemotherapies used to treat ovarian cancer, such as 
doxorubicin or topotecan. Moreover, aside from chemotherapies, PARP inhibitors are 
used to treat patients with BRCA-mutated ovarian cancer (G. Kim et al. 2015). The 
correlation between PARP inhibitor sensitivity and RTK expression could also be 
determined.  
 Similarly to chapter 2, all in vivo work was performed in immunocompromised 
mice. The effects of dual IGF-1R and ErbB3 inhibition should also be investigated in an 
immune-competent model of ovarian cancer. Female chickens represent a strong 
spontaneous and immunocompetent model of ovarian cancer (Barua et al. 2009), with a 
staggering 35% of egg-laying hens developing ovarian cancer before the age of 4 
(Hawkridge 2014). After testing istiratumab for cross-reactivity to chicken IGF-1R and 
ErbB3 and producing istiratumab on a chicken IgG backbone, it can be assessed for in 
vivo efficacy both alone and in combination with chemotherapy as in chapter 3. Both the 
orthotopic and immunocompetent nature of this model would provide more clinically 
translatable data.  
6.3 Tumor Necrosis Factor Alpha Sustains Human Umbilical Vein Endothelial Cells 
Angiogenesis Through TNFR1 
 In chapter 4 we establish an in vitro assay to assess effects of TNF stimulation on 
HUVEC tube formation using the Angiogenesis Analyzer for ImageJ. The results showed 
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that this cytokine is not inducing tube formation, but rather prolonging tube maintenance. 
Furthermore, we showed that this TNF induced effect is entirely driven through TNFR1 
not TNFR2, implying that therapeutically targeting TNFR2 for treatment of cancer 
should have no effect on angiogenesis. Growth factors such as IGF-1 (Lin et al. 2017), 
HRG (Yen et al. 2000), and others (Ucuzian et al. 2010) have also been implicated in 
driving angiogenesis, and this assay could be used to assess whether they affect rate of 
formation or degree of tube maintenance. If this proves to be the case, then RTK 
targeting therapies may also alter angiogenesis, expanding their mechanism of action 
beyond signaling inhibitor.  
Different timing and scheduling of treatment (such as supplementing growth 
factor or cytokine only after tubes have been formed) could be performed to assess 
whether the cytokines affect formation or maintenance of the tubes. Furthermore, 
mitomycin could be added to the experiment to prevent cells from dividing during the 
assay to elucidate whether cells are proliferating or migrating during the tube formation 
process. If mitomycin does not alter rate of tube formation, then it can be concluded the 
endothelial tube formation is driven entirely by cell migration.  
Orthogonal experimental methods can be used to validate the work presented in 
chapter 4. Co-culturing HUVEC cells on a fibroblast support may more closely represent 
the tumor microenvironment. The effects of TNF on in vivo angiogenesis can also be 
assessed. A Matrigel plug supplemented with different cytokine conditions could be 
implanted into mice. These mice could be treated with various antibodies inhibiting the 
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relevant receptor, sacrificed and their Matrigel plug histologically assessed for vascular 
invasion. Additionally, angiogenesis could be assessed histologically in tumors could be 
grown in mice. Positive results from this experiment would validate the in vitro HUVEC 
model of angiogenesis. 
6.4 Elucidating the contribution of Tumor Necrosis Factor (TNF) Receptor 2 
(TNFR2) to TNF response of cancer cells and determining drivers of in vivo 
response to an anti-TNFR2 therapeutic. 
 In chapter 5, after first demonstrating proof of concept that targeting TNFR2 with 
an antibody can have therapeutic efficacy in eight syngeneic mouse models of cancer, we 
went on to demonstrate that cell line TNFR2 expression does not appear to contribute to 
in vivo anti-TNFR2 efficacy or TNF induced response in vitro. TNFR2 has a second 
ligand, lymphotoxin (LT) (Bodmer, Schneider, and Tschopp 2002). It is possible that 
cancer cell line response to LT will be different from TNF response. Cell line 
responsiveness to LT should be determined then correlated to in vivo anti-TNFR2 
efficacy. In the event there is a correlation between TNFR2 expression and LT response, 
the anti-TNFR2 may have an additional mechanism of action by directly affecting the 
cancer cells.  
Although TNFR2 knock-out cells showed no alteration in which signaling 
pathways are activated in response to TNF stimulation, the TNFR2 knock-out cell line 
cells lost sensitivity to TNF stimulation both in terms of signaling intensity and 
proliferation. The use of ligand competitive anti-TNFR1 and anti-TNFR2 antibodies 
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confirmed that both receptors contribute to TNF induced signaling events on cancer cell 
lines. In these experiments we didn’t account for possible receptor turnover, and it is 
possible the rate of receptor degradation and re-synthesis are affecting the results. In 
figure 5.4B, the combination of TNFR1 and TNFR2 targeting antibodies does not fully 
block TNF response, despite using a concentration of antibody which should fully occupy 
cell surface TNFR1 and TNFR2. These experiments could be repeated under conditions 
which inhibit new protein synthesis, such as addition of cycloheximide, or under 
conditions which prevent receptor degradation, such as addition of a proteasome or 
lysosome inhibitor. In the event that inhibiting re-synthesis of proteins enhances response 
to anti-TNFR1 or anti-TNFR2 antibodies, it would suggest that receptor turn-over is 
leading to suboptimal blockade of the receptors despite the use of saturating 
concentrations of antibody.  
In figure 5.6, we demonstrated that anti-TNFR2 efficacy is lost in immune-
deficient nude mice, which lack mature T cell population, and in figure 5.7 that efficacy 
was also lost in mice depleted of CD8 T cells. Taken together these data suggest that this 
in vivo efficacy is dependent upon CD8 T cells. Moreover, in vivo efficacy was 
maintained in tumors generated from cancer cell lines of TNFR2 knock-out origin, 
suggesting that blockade of TNFR2 on cancer cells themselves is not involved in the 
therapeutic effect of the antibody. Interestingly, the anti-TNFR2 therapeutic may be more 
efficacious when cancer cell lines are TNFR2 knock-out as compared to wild-type 
TNFR2. This must be confirmed by generating TNFR2 knock-out variants for all eight 
cell lines and retesting them for in vivo efficacy. We hypothesize that knocking out 
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TNFR2 may be increasing free TNF within the tumor microenvironment by preventing it 
from becoming occupied by cancer cell TNFR2, thereby changing and potentially 
enhancing the localized immune response by increased the concentration of available 
TNF for immune cells to bind.  
Although there were no effects of antibody clustering on the cancer cell line 
proliferation, it appears that anti-TNFR2 clustering is required for in vivo CD8 cell 
agonism as demonstrated by both the ex vivo CD8 expansion assay and requirement of Fc 
receptor engagement for in vivo efficacy. The anti-TNFR2 could have multiple distinct 
mechanisms of action. For example, aside from having a clustering effect Fc function is 
associated with direct cell depletion and cell killing (Kohrt et al. 2015). Further tests are 
required to determine if anti-TNFR2 binding to TNFR2 can induce cell depletion. For 
example, anti-TNFR2 mediated depletion of regulatory T cells may also be able to drive 
in vivo efficacy.   
6.5 Conclusion 
 This work provides a greater mechanistic understanding of how therapeutically 
targeting cell surface receptors can lead to anti-cancer efficacy. Given the adaptive nature 
of the tumor microenvironment, adding tools to the physician’s toolbox of available anti-
cancer treatment will without a doubt have a positive impact on the lives of patients and 
their families.  
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